

## FRONT MATTER

# Infection control strategies in essential industries: using COVID-19 in the food industry to model economic and public health trade-offs

Short title: **Infection control trade-offs**

## Authors

Christopher Henry<sup>1</sup>, Ece Bulut<sup>1</sup>, Sarah I. Murphy<sup>1</sup>, Claire Zoellner<sup>2</sup>, Aaron Adalja<sup>3</sup>, Diane Wetherington<sup>4</sup>, Martin Wiedmann<sup>5</sup>, Samuel Alcaine<sup>5</sup>, Renata Ivanek<sup>1\*</sup>

## Affiliations

<sup>1</sup>Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA

<sup>2</sup>iFoodDecisionSciences, Seattle, WA, USA

<sup>3</sup>Nolan School of Hotel Administration, Cornell SC Johnson College of Business, Cornell University, Ithaca, NY, USA

<sup>4</sup>iDecisionSciences, Seattle, WA, USA

<sup>5</sup>Department of Food Science, College of Agriculture and Life Sciences, Cornell University, Ithaca, NY, USA

\*Corresponding author: Renata Ivanek [ri25@cornell.edu](mailto:ri25@cornell.edu)

## Abstract

The COVID-19 pandemic exposed challenges of balancing public health and economic goals of infection control in essential industries like food production. To enhance decision-making during future outbreaks, we developed a customizable agent-based model (FInd CoV Control) that predicts and counterfactually compares COVID-19 transmission in a food production operation under various interventions. The model tracks the number of infections as well as economic outcomes (e.g., number of unavailable workers, direct expenses, production losses). The results revealed strong trade-offs between public health and economic impacts of interventions. Temperature screening and virus testing protect public health but have substantial economic downsides. Vaccination, while inexpensive, is too slow as a reactive strategy. Intensive physical distancing and biosafety interventions prove cost-effective. The variability and bimodality in predicted impacts of interventions caution against relying on single-operation real-world data for decision-making. These findings underscore the need for a proactive infrastructure capable of rapidly developing integrated infection-economic mechanistic models to guide infection control, policy-making, and socially acceptable decisions.

## Teaser

COVID-19 model helps navigate trade-offs between public health and economic impacts of infection control interventions in essential industries.

## 45 MAIN TEXT

### 46 47 Introduction

48 The United States (US) food industry, known for its labor-intensive nature (1), was  
49 significantly affected by the Coronavirus disease 2019 (COVID-19) pandemic, alongside other  
50 essential industry sectors (2). During the early phases of the pandemic, food facilities/operations  
51 abroad and in the US were forced to close or reduce production due to labor shortages (2, 3). US  
52 livestock processing, including poultry, pig, and cattle slaughter, was reduced by up to 45%,  
53 resulting in job losses, financial impacts, retail shortages and loss of animals (4, 5). During the  
54 COVID-19 pandemic in 2020, the combined value of production for beef, pork, broilers, turkeys,  
55 eggs and milk was reduced down by \$12.8 billion in the US, to 9% below the pre-pandemic  
56 forecast for 2020, based on price and production quantity projections (6). Dairy supply chain  
57 disruptions caused increased milk dumping in the US, where 2.5% of all federally regulated milk  
58 was dumped compared to 0.2-0.5% dumping recorded in the normal course of production (7). By  
59 September 2021, nearly 100,000 workers in US meatpacking facilities, food processing facilities,  
60 and farms were reported positive for COVID-19, most of which were from meatpacking facilities  
61 (65%) and other food processing facilities (21%) (8); importantly, these statistics are likely  
62 underestimates (9). These outbreaks drove infection rates in rural communities, as individuals  
63 infected at work transmitted their infection to others outside of work (10). By the end of 2020,  
64 COVID-19 cases attributable to meatpacking facilities were reported to be the source of an  
65 estimated 334,000 infections in the US, with associated mortality and morbidity costs totaling  
66 more than US\$11.2 billion (11). These impacts affected the functioning of the national food  
67 supply chain.

68 Several mitigation strategies have been considered, encouraged, or enforced to control the  
69 spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the US food  
70 industry (12, 13). These control strategies include vaccination, practicing physical distancing, use  
71 of face coverings, screening for infection, practicing personal hygiene (e.g., hand washing),  
72 cleaning and disinfection of the working environments, ventilation improvements, and  
73 minimizing community spread. Produce (i.e., fruit and vegetable) farms and food processing  
74 facilities, while having certain features in common, vary greatly in size, physical characteristics,  
75 and organizational structure (14). Thereafter, for brevity, we use ‘operation’ when referring to any  
76 individual produce farm operation or food processing facility. Food operation’s varying locations,  
77 policies, and workforce demographics have resulted in significant differences in worker histories  
78 with respect to vaccination, boosting, and past infection (15, 16). The diversity of operations and  
79 mitigations have led to strong interest from industry stakeholders in modeling tools tailored to the  
80 particular characteristics of their individual operations (17) to aid them in making predictions,  
81 such as regarding the expected outbreak dynamics and impacts of possible interventions, and  
82 decisions, such as what level of investments to make in biosafety measures or when to start or  
83 stop an intervention (personal communication with the Industry Advisory Council for the study).  
84 Importantly, the evaluation of COVID-19 mitigation strategies should be based not only on public  
85 health metrics but also on economic metrics that account for the production losses in the operation  
86 due to worker shortages or strict infection control strategies, as well as considerations of negative  
87 societal impacts of food supply chain disruptions and possible food shortages.

88 Several mathematical models (18-30) have been developed to evaluate and compare  
89 COVID-19 mitigation strategies and assess their effectiveness across different levels of  
90 compliance. These models are primarily designed for national scale assessments (21, 25-27) but  
91 also include more localized communities, encompassing cities (24, 28, 30), closed societies with  
92 shared environments (19, 29), and even smaller communities in universities (22), companies (20,  
93 23), and office spaces (18). Some of the evaluated interventions include physical distancing, mask  
94 use, vaccination, asymptomatic/symptomatic testing, contact tracing, quarantine, restrictions on

95 travel, isolation, and school closures (18, 19, 26-28). While most of the modeling studies  
96 concentrate on health outcomes in the general population, only a handful have considered the  
97 health of individuals within workplace settings. These settings include a generalized company  
98 building (20), an oil and gas facility (23), a meatpacking plant (29), and a university building  
99 (22). These studies have accounted for the complex process of disease transmission between  
100 individuals by using agent-based models (ABMs), which can simulate employees' decisions based  
101 on their social and physical profiles. A few studies have also utilized ABMs to simulate the  
102 economic impacts of COVID-19 (24, 25, 30, 31). Nevertheless, there remains a need for models  
103 that explore COVID-19 spread as well as the health and economic impacts of mitigation strategies  
104 in individual food operations to help prevent similar impacts in future infection outbreaks.

105 Here, we provide **Food Industry CoVid-19 Control Tool** (FInd CoV Control), a  
106 customizable tool based on an ABM developed to simulate COVID-19 transmission dynamics in  
107 the food industry work environment. We integrated the ABM with an economic model to predict  
108 the direct and (certain) indirect costs of interventions. Using COVID-19 in the food industry  
109 workforce as a model system, our objective was to develop a tool that helps policymakers and  
110 individual operations navigate tradeoffs between public health and economic impacts of infection  
111 control interventions in an essential industry.

## 112 113 114 115 **Results**

### 116 **Model setup**

117 FInd CoV Control consists of three modules: Employee population, Work environment,  
118 and Disease transmission (**Figure 1A**; definitions in **Text S1**, further details in **Texts S2-S4** and  
119 **Tables S1-S13**). The Employee population includes all employees (agents) in a modeled  
120 operation, each of which is characterized by a set of attributes (**Table 1**). The Work environment  
121 module defines the characteristics of the work environment in terms of a produce farm or  
122 processing facility setting (thereafter referred to as ‘farm’ and ‘facility’ for brevity), shift schedule  
123 (**Figure 1B.i**), and agent hierarchy and contact network (**Figures 1B.ii, 1B.iii, and S1**). The  
124 Disease transmission module tracks COVID-19 infection spread in a population representing  
125 employees of a operation, using an elaborated variant of a "Susceptible-Exposed-Infectious-  
126 Recovered-Susceptible" (SEIRS) model (**Figure 1C**). FInd CoV Control is customized to the  
127 population and work environment of a particular operation based on the user-set parameters  
128 (**Table 2**), which are also used to calculate the number of agents with various immunity  
129 trajectories and histories (**Table 3**). We used FInd CoV Control to make predictions about  
130 COVID-19 transmission dynamics following the arrival at work of an index case infected outside  
131 the workplace, both under a no-intervention “baseline” and under various interventions. The  
132 evaluated interventions included: a temperature screening intervention, three virus testing  
133 interventions, a total of five primary vaccination and/or boosting-promoting interventions, and  
134 three direct basic reproduction number ( $R_0$ )-reduction (physical distancing and/or biosafety)  
135 interventions (**Figure 1A**). The baseline and interventions were simulated in a way that allows  
136 counterfactual comparisons. Interventions were evaluated using two groups of metrics: (i) Public  
137 health: the number of employees with symptomatic and asymptomatic infection (and total  
138 infected); and the initial effective reproductive number ( $R_{eff}$ ) and (ii) Economic: the number of  
139 employees unavailable to work; the fraction of shifts with employee shortage; and total direct  
140 expenses, production losses, and total costs associated with an intervention (expressed in US\$)  
141 (**Figure 1C**). While economic effects are often interrelated and ripple over multiple dimensions,  
142 in FInd Cov Control, the economic analysis is limited to the costs directly borne by operations

(Text S5) and is meant to serve as a reference, together with the infection model, for employers' decision-making.

## Model validation

FInd CoV Control was validated with publicly available data on outbreaks from early in the pandemic when few, if any, interventions would have been implemented. Specifically, for produce farm operations, FInd CoV Control was validated using two outbreaks, one on a farm with shared (i.e., employer-provided dormitory style) housing and one with a mix of shared and individual housing. For processing facilities, FInd CoV Control was validated using three outbreaks in facilities with individual housing, one in each of the dairy, pork, and produce processing facilities. These outbreaks and validation results are described in Text S6. The results of the validation analysis indicated a reasonable fit between the reported data and model predictions.

## Main results

We begin by presenting a representative set of results over a 90-day simulation, for a facility with 103 employees, shared housing, and otherwise default parameters (see Tables 2 and 4), in Figures 2, 3, and 4. Results for the farm model with similar parameters are qualitatively comparable, and outcome estimates for a larger facility with 1,003 employees (Figures S2, S3 and S4) are generally similar with the main differences being later-peaking outbreaks (due to greater incidence growth required to saturate the larger population), and an associated modest increase in the effectiveness of some interventions. There is also a modest reduction in noisiness, which leads to a reduction in the probability of experiencing labor shortages in individual runs, given that the average outcome is not to experience a shortage in either case. Differences associated with shared versus individual housing are covered in the "Scenario analysis" section (and Text S7).

Results pertaining to the number of symptomatic infections, our primary public-health outcome, are presented in Figure 2. There is little qualitative difference between the curves depicting the mean incidence (Figure 2A) and mean prevalence (Figure 2B) of symptomatic infection over time, although there is a difference in scale and a slight difference in location (with peak incidence occurring slightly prior to peak prevalence) and noisiness (with more visual noise in the incidence vs prevalence curves). This result is expected, so to avoid redundancy, we focus on (cumulative) incidence in the remaining panels.

### *Bimodality and variability in symptomatic infections*

For all interventions (including the no-intervention baseline), over 40% of all runs result in no symptomatic infections at all (Figure 2C), and as a result, the number of symptomatic infections for a given intervention is strongly bimodal at baseline and for all interventions except for moderate viral testing ( $p = 0.3$ , i.e., 30% of scheduled workers tested each shift, amounting to testing every worker 1.5 times per week), high-intensity viral testing ( $p = 1$ , i.e., every worker scheduled for testing each shift), and "high-effectiveness (-80%  $R_0$ ) Physical distancing/Biosafety" (Figure 2D). This reflects that, in the absence of repeated reintroduction from the broader community, a major source of variance is the possibility of early stochastic die-off, even at an initial  $R_{eff}$ . well above 1 (e.g.,  $R_{eff} = 2.52$  at baseline for this scenario), which effectively partitions the vast majority of outcomes (for interventions for which  $R_{eff}$  remains appreciably above 1) into two modal regions (groups) with respect to the outbreak size: (i) small or non-existent outbreaks and (ii) large outbreaks. At baseline, over the 90 days since the introduction of an index case, group (i) has 0-12 (median 0, mean 0.60) total infections, not including the index case, and 0-4 symptomatic infections (median 0, mean 0.16), with no infected individuals left by the end of simulation, while group (ii) has 51-97 total infections (median 82,



193 mean 81.9), not including the index case, and 17-49 (median 34, mean 33.1) symptomatic  
194 infections. There are also 5 runs (out of 1000) that fell between these two groups, with 21-42 total  
195 infections (median 39, mean 35.8) and 5-14 symptomatic infections (median 11, mean 10.6).

### 196 ***Bimodality and variability in counterfactual effects of interventions***

197 We can refine and expand observations detailed in the previous section by taking  
198 advantage of the steps we have taken to make counterfactual comparisons as precise as possible  
199 (see “Interventions” section); specifically, the  $i$ -th run of the model with any intervention  
200 corresponds in a meaningful way to the  $i$ -th run of the model at baseline, with the difference  
201 between the two being attributable solely the intervention. Consequently, it is meaningful to  
202 examine the pairwise differences, with respect to a particular outcome, between corresponding  
203 runs with and without a given intervention. The distributions of these pairwise differences, for  
204 runs that have at least one symptomatic infection at baseline, are presented in **Figure 2E**. There,  
205 we can see that there is not only a great deal of variance in outcomes within an intervention (or  
206 within the baseline), but also a substantial variance in the counterfactual effects of an  
207 intervention. This is meaningful, considering that the individual ABM runs reflect the real-world  
208 variation in epidemiologic outcomes, and the model provides a view into the counterfactual  
209 comparisons within individual runs that cannot be observed in the real world. To illustrate this  
210 phenomenon, a single intervention can be examined in detail (**Figure 2E**). The “moderate-  
211 effectiveness (-40%  $R_0$ ) Physical distancing/Biosafety” intervention is modestly beneficial on  
212 average (mean reduction in number of symptomatic infections = 10.4) and in its typical  
213 performance (median reduction = 6). Nevertheless, it can be extremely effective in individual runs  
214 (maximum reduction of 45, close to the maximum across all interventions of 48). On the other  
215 hand, it can prove entirely ineffective or even counterfactually *counterproductive* in other  
216 individual runs (61 runs with no reduction in number of symptomatic infections, and 68 runs with  
217 an *increase* of 1-20. This is due to the timing and chance effects as explained in **Text S8**, where  
218 results for additional interventions (temperature screening and viral testing) are also illustrated.  
219 We can also note that most of these distributions of pairwise differences are themselves bimodal,  
220 reflecting two different ways that an intervention can counterfactually affect a run that produces  
221 large outbreak in the no-intervention scenario. In these counterfactual comparisons, on the one  
222 hand, an intervention may prevent a large outbreak altogether, producing a data point in the high-  
223 effectiveness modal region in **Figure 2E** (and contributing to the difference in the number of  
224 large outbreaks between the intervention and no-intervention scenarios in **Figure 2D**).  
225 Alternatively, it may produce a smaller difference in the outbreak size (or none at all), producing  
226 a data point in the low-effectiveness modal region (and still contributing a large outbreak to both  
227 the intervention and no-intervention scenarios in **Figure 2D**). Depending on the intervention, one  
228 of these modal regions may be extremely small, or they may both be substantial.

229 We can further refine these observations by considering the change in number of  
230 symptomatic infections as a fraction of the baseline number of symptomatic infections (**Figure**  
231 **2F**; **Figure S2F** for a large facility). In particular, for those interventions with a significant  
232 fraction of runs in the high-effectiveness modal region, the primary way that they shift runs from  
233 having large outbreaks in the no-intervention scenario, to not having large outbreaks in the  
234 presence of the intervention is, by causing them to have no symptomatic infections at all; the  
235 apparently symmetrical lower modes seen in **Figure 2E** are primarily produced by variation in the  
236 number of infections (in a *large* outbreak) at baseline, not by variation in the number of infections  
237 (in a small or (effectively) non-existent outbreak) under the intervention.

### 238 ***“All good things in moderation” may backfire in viral testing***

239 Based on the different patterns of effects in **Figure 2F**, the most effective reductions in  
240 symptomatic infections are seen for moderate- and high-intensity viral testing. **Figure 4** (**Figure**  
242

**S4** for a large facility) shows that viral testing at a fairly high rate is also generally more costly. In the case of high-intensity viral testing, this cost is overwhelmingly due to direct intervention expenses (primarily the cost of test kits), and this result is robust across a variety of scenarios (not shown). This is also true in most runs for moderate-intensity viral testing, but in some runs, moderate-intensity viral testing can result in significant costs due to both direct intervention expenses and production losses. The latter reflects the ability of testing at a “moderate” rate ( $p=0.3$ /working day) to generate a “worst of both worlds” scenario. This scenario generates large numbers of employees who are isolated at the same time, resulting in large numbers of worker-shifts missed due to isolation, yet, infected employees are not identified and isolated fast enough to prevent a large outbreak from occurring. A more frequent version of this (rarely producing > 15% absences on a production shift, which is considered to cause shortages and, thus, production losses) can be seen for low-intensity viral testing ( $p = 0.05$ /work day) where mean and median increases in unavailability are both greatest (**Figures 3E and 3F; Figures S3E and S3F** for a large facility). This observed pattern reinforces and extends the result from prior research that existent but inadequate larger-scale (city-level) non-pharmaceutical interventions can result in what the authors describe as a “dual blow of increased deaths and unemployment,” which fall disproportionately on low-income workers (30).

### ***Health benefits of physical distancing/biosafety interventions at low cost***

Finally, the next-most effective intervention in preventing symptomatic infections, after the moderate- and high-intensity viral testing interventions is the “high-effectiveness (-80%  $R_0$ ) Physical distancing/Biosafety” intervention (**Figure 2F**), for illustration purposes represented by a combination of masking, face shield use, and ventilation improvements. We found this to be much more effective than the “moderate-effectiveness (-40%  $R_0$ ) Physical distancing/Biosafety” intervention (represented by masking and face shield use, without ventilation improvements), but only modestly more costly (and substantially less costly than the more effective viral testing interventions) (**Figure 4**).

### **Scenario analysis**

For our scenario analysis, we first defined several elements whose effects and interactions with intervention effects we wished to examine (**Figure 5**). These scenario elements were “setting” (“farm” vs. “facility”), “housing” (“individual” vs. “shared”), “vaccinated” (“high” (based on US national levels in early 2022 (32,33)) vs. “none”), and “recovered” (“high” US national levels (32, 34, 35) vs. “none”) (details in section **Text S7** and **Table S12**). We then conducted a full factorial analysis for all 16 combinations of these four factors (and for all 13 intervention scenarios) in the default facility size of 103 workers over 90-day-long simulation runs. Many combinations of these scenarios are intended to represent limiting cases, rather than realistic scenarios, e.g., a scenario with both “vaccinated” = “high” and “recovered” = “none” represents a limiting case of relatively high vaccination and no history of infection. Results of this analysis, evaluated using regression trees for each of the three primary outcomes (symptomatic infections, worker-shifts unavailable, and total cost) and the two separate contributors to total cost (production losses and intervention expenses), indicated that, for outcomes other than production losses, the effects of “setting” were relatively limited, and mostly pertained to which *other* effects were strong enough to be included in the pruned partition trees. Because transmission in the two settings is defined by the user-settable value of  $R_0$  (**Table 2**), which was kept the same between the two settings, the observed differences between settings can be attributed to differences in the work environment (**Figures 1B and S1**). In general, the evaluated outcomes were slightly higher for the “facility” setting than for the “farm” setting. Because of this, and to omit explanations of the different equations used to set default production-per-week in the two different settings, we

293 chose to describe results from the facility model here. Because total cost is simply a sum of  
294 intervention expenses and production losses, and because various factors affect each of those  
295 components differently, we will focus our discussion on each cost individually (results presented  
296 in **Figure 5**).

### 297 ***Health and economic outcomes are driven by the interaction between the worker infection*** 298 ***history and intervention intensity***

300 For almost all evaluated outcomes, the two biggest factors driving outcomes are intensity  
301 of virus testing intervention and “recovered” (i.e., whether the employee population has a  
302 significant history of natural infection) (**Figure 5**); the only exception is intervention expenses  
303 (**Figure 5C**), for which intensity of virus testing was the strongest factor, but “recovered” did not  
304 produce a sufficient impact to appear in the regression tree. While “recovered” being “high”  
305 (rather than “none”) had a desirable impact (i.e., produced lower symptomatic infections,  
306 unavailability, and intervention expenses) on all outcomes for which it was relevant, the effects of  
307 virus testing were more variable. Symptomatic infections are minimized by viral testing at a rate  
308 high enough to reliably control an outbreak before it can get large (testing every worker every  
309 shift or roughly every 3 shifts ( $p = 1$  or  $0.3/\text{work day}$ , respectively)) (**Figure 5A**). Unavailability  
310 (**Figure 5B**), on the other hand, is lowest when *either* testing is non-existent (and so no workers  
311 are isolated as a result of testing, but only as a result of hospitalization) *or* testing is extremely  
312 intensive (and so the outbreak(s) is/are rapidly contained;  $p = 1/\text{work day}$ ); however, even such  
313 intense testing may be insufficient to achieve a reasonable level of control in the face of a  
314 population with insufficient natural and hybrid immunity (“recovered” = “none”) and constant  
315 reintroduction (housing = “individual”). Conversely, unavailability is *highest* when the testing  
316 rate is intermediate ( $p = 0.05$  or, even more so,  $p = 0.3/\text{work day}$ ), resulting in enough  
317 asymptomatic and mildly symptomatic cases being detected to increase unavailability, but not  
318 enough to rapidly contain the outbreak(s). Similarly, production losses (which are driven by  
319 unavailability of  $\geq 15\%$  on a production shift) are highest when  $p = 0.3/\text{work day}$ , to the point that  
320 recursive partitioning with default parameters results in further division only of the node with  $p =$   
321  $0.3$ ; all scenario-intervention combinations with either a lower ( $p = 0$ ,  $p = 0.05$ ) or a higher ( $p = 1$ )  
322 rate of virus testing are combined in a single node (**Figure 5D**). Intervention expenses, on the  
323 other hand, move in an opposite pattern to symptomatic infections, and are highest when the rate  
324 of viral testing per work day is highest ( $p = 1$ ), and lowest when it is low ( $p = 0.05$ ) or non-  
325 existent ( $p = 0$ ) (**Figure 5C**).

### 326 ***Strongest outcome drivers are viral testing intensity and history of natural infection***

327 While “recovered” is consistently more important than “vaccinated” (i.e., splits defined by  
328 it occur closer to the root of each tree, where either occurs at all), and both share a uniformly  
329 desirable effect (where they show any effect at all), the interaction of the two is more complex:  
330 For production losses, there is only a split defined by “vaccinated” in a branch in which  
331 “recovered” is set to “none,” but for symptomatic infections, the reverse is true – the only split  
332 defined by “vaccinated” occurs in a branch in which “recovered” is set to “high.” In more  
333 conceptual terms, this amounts to saying that, at the population level, immunity resulting from  
334 recovery from natural infection plays a stronger role in determining a wide range of simulation  
335 outcomes than immunity resulting from vaccination - perhaps an unsurprising result late in a  
336 pandemic; whether the interaction of these two is sub-additive or super-additive depends on  
337 which outcome one is considering. In particular, with respect to symptomatic infections, there  
338 may be a synergistic effect of vaccination and recovery from natural infection, likely reflecting  
339 the strong protective effect of modeled hybrid immunity. For production losses, on the other hand,  
340 vaccination is less influential in the presence of moderate-to-high levels of natural recovery  
341 within the past year. This likely reflects the threshold effect in our model of production losses (of  
342

15%) – in the presence of sufficient protection from natural recovery, the probability of suffering production losses at all may be low enough, even in the absence of vaccination, to reduce the importance of vaccination in predicting or determining that outcome.

The only panel from which the “recovered” factor is absent, or even not one of the two strongest factors, is **Figure 5C** Intervention Expenses; the “vaccinated” factor is absent from this panel as well (although the cost of giving workers time off for vaccination is accounted for). This is unsurprising, given that intervention expenses are driven far more - at least, for the relatively simple interventions that we consider in this analysis - by what interventions one decides to implement than by transmission dynamics; as a result, *no* scenario parameters appear in it. The only split that does, other than the virus testing splits, is a split by whether there is a Physical distancing/Biosafety (“ $R_0$  reduction”) intervention, which raises costs (mean cost = US\$7,171 vs. US\$1,108; **Text S5**) over the alternative (a weighted average of no-intervention baseline, temperature screening, and vaccination and/or boosting interventions), in line with what we would expect. Temperature screening, being similar in certain respects to virus testing, but substantially cheaper and generally substantially less effective, appears only in the tree for unavailability (**Figure 5B**), where its use increases unavailability, more than a maximal rate ( $p = 1$ ) of viral testing (117 vs.  $85 = (26 + 164) / 2$ ).

### ***Intervention effectiveness is highly sensitive to the degree of community transmission***

Housing affects both unavailability (**Figure 5B**) and number of symptomatic infections (**Figure 5A**); both are higher when housing is “individual”. This is not to say that “shared” dormitory housing is a poorer environment for transmission than individual housing; rather, it reflects the role of community transmission in creating opportunities for reintroduction of infection from outside the employee population. This result is confirmed and elaborated by tests in **Text S7**, where we treat presence or absence of community transmission and presence or absence of dormitory transmission as separate factors. In line with this, additional analyses (**Text S7**) further indicate that our predictions about intervention effectiveness can be highly sensitive to the degree of community transmission.

### ***“ $R_0$ reduction” strategies are cost-effective***

Physical distancing/Biosafety interventions (“ $R_0$  reduction”) can reduce the number of symptomatic infections (when sufficiently effective) with minor increase in intervention expenses (**Figures 5A** and **5C**, respectively). This suggests that highly effective  $R_0$  reduction strategies are cost-effective and, hence, should be prioritized for implementation.

### **Sensitivity analysis**

To test the sensitivity of our model to a variety of parameters that are not user-settable, we visually and numerically examined the results when each of these parameters was varied, using a One Factor at a Time (OFAT) approach, with all other parameters (both user-settable and otherwise) at their default values, except that we examined a facility with “individual” housing. In this analysis, we focused on our three primary outcomes -- total symptomatic infections, total number of worker-shifts missed, and total cost over the simulation length -- and, additionally, on the employee-to-employee (contribution to the) effective reproduction number ( $R_{eff.}$ ) at the start of simulation. In **Figure 6**, we present results for 5 representative intervention scenarios, for the 5 parameters that showed the greatest sensitivity across all evaluated parameter-outcome combinations. For each of these parameters, we present the mean value for each outcome when the parameter is halved, when it is left (along with all other parameters) at its default value (**Table S14**), and when it is doubled. Symptomatic infections are most strongly affected by parameters defining the mean duration ( $\mu_{IM}$ ) of mild symptomatic infection and relative per-contact



393 probability of transmission ( $\beta_{IM}$ ) during this stage), followed by a parameter ( $\varphi$ ) governing the  
394 protection from developing symptomatic disease provided by Recovered and Hybrid immunity  
395 (**Text S8B**). Worker-shifts missed are most strongly affected by the relative frequency of severe  
396 infection, given any symptomatic infection ( $\psi$ ), followed by the mean duration of severe infection  
397 ( $\mu_{IS}$ ), while the effects of these 5 parameters on  $R_{eff}$  and total cost were generally smaller (**Text**  
398 **S8C**).

## 402 **Discussion**

403 This study presents an ABM for tracking COVID-19 transmission and control in the food  
404 industry workforce to serve as a decision-support tool that can be used to mitigate the impacts of  
405 infectious disease outbreaks on essential worker populations and the food supply chain. The  
406 model can be customized to produce farm or processing facility settings, the type of employee  
407 housing predominantly used, as well as the vaccination and infection history and age  
408 characteristics of the workforce. Additionally, the model allows testing of a number of  
409 interventions and evaluating them counterfactually with regard to several public health and  
410 economic outcomes, and interpretation of predictions at the population and individual operation  
411 levels. The two strongest themes in our results are bimodality and trade-offs. Finally, the model  
412 also provides insights about effectiveness of different possible interventions and areas requiring  
413 further research. The developed model is expected to facilitate the food industry's resilience and  
414 responsiveness to COVID-19 and similar future outbreaks, as well as to help navigate tradeoffs  
415 between public health and economic impacts of infection control interventions in essential  
416 industries.

### 419 **Bimodality and variability in outcomes and intervention effectiveness**

420 The simulation runs of FInd CoV Control can be interpreted to represent a population of  
421 operations with similar workforces and work environments. The simulation predicts how an  
422 outbreak would unfold in each operation (i.e., run) following infection introduction, and in  
423 counterfactual versions of the same operation that implemented different interventions. This  
424 allows us to interpret the predictions at the population level, answering questions such as: "What  
425 fraction of operations would experience certain health and economic outcomes?" Not only are  
426 most outcome distributions bimodal, but the counterfactual effects of most potential interventions  
427 are bimodal as well. Relatively ineffective (on average) interventions (e.g., temperature  
428 screening) not only sometimes appear to produce good outcomes, but also genuinely produce  
429 strong positive effects in a counterfactual sense, albeit with low probability. This is a particular  
430 consequence of a broader phenomenon: Much of the positive effect (when there is one, and  
431 especially when there is a *strong* one) of effective and ineffective interventions alike comes from  
432 their potential to control an outbreak at a very early stage, often before there is a single  
433 symptomatic infection. This presents a further challenge for "reactive" interventions (i.e., those  
434 implemented after the detection of a first infected case), above and beyond the issue of how  
435 quickly they can be deployed; by the time that operation managers (or policy-makers) are aware  
436 of an outbreak, the best opportunity to control it has already passed. This further supports the  
437 value of tools like FInd CoV Control that can be used as planning/forecasting tools, perhaps  
438 quarterly or on a rolling 90-day basis, to proactively prepare for the potential disease introduction.

439 Conversely, even fairly effective (on average) interventions can result in little or no effect  
440 in individual outbreaks. Some may even be capable, albeit with low probability, of producing  
441 counterfactually worse outcomes. This can largely be attributed to matters of timing of infection,

442 for individuals who are infected at some point in either case; this can have an impact both through  
443 chance occurrence of opportunities for secondary transmission at particular points in time, and  
444 through the increase in probability of symptomatic infection that comes with increased time since  
445 last immunity event (i.e., last vaccination or last recovery from natural infection). Together, these  
446 possibilities, reflected in the bimodality in outcomes, further increase the (already substantial)  
447 real-world probability of misleading conclusions from anecdotal observations in individual  
448 operations, and thereby reinforce the importance of mechanistic, predictive models such as FInd  
449 Cov Control. As an alternative, data-driven evidence-based recommendations would require  
450 large-scale data collection, including time-series information on the infection spread and control  
451 (e.g., incidence of symptomatic and asymptomatic infections, results of diagnostics tests,  
452 vaccination history, infection, and isolation-related absence from work). Importantly, the data  
453 collected would need to include detailed metadata that explain the context of infection spread and  
454 control in individual work environments, because the characteristics of the work environment  
455 may serve as effect modifiers on the infection dynamics and intervention effectiveness. There are  
456 limited examples of studies of COVID-19 epidemiology in the food industry work environments  
457 (36, 37). These studies highlight the potential for rapid transmission of SARS-CoV-2 in the food  
458 industry's work settings, which they attributed to the close arrangement of workstations and  
459 extended contact among employees. The data made available by the food operations where the  
460 investigations took place played a crucial role in enabling these studies. Our findings emphasize  
461 the need for much larger-scale data collection. However, given the cost, technical, and  
462 confidentiality-related obstacles to collecting such data, the prospect of purely data-driven  
463 decision-support models is dim. Collecting confidential data on infection spread in a food  
464 operation for the operation's private decision-making is of course encouraged. However, it should  
465 be noted that in isolation from data on infection transmission in other comparable operations, such  
466 data will have a limited value even for the operations' private use since the data will represent just  
467 one of many possible ways an outbreak (with or without an intervention) has unfolded as  
468 demonstrated by the model simulations. This underscores the need to proactively develop  
469 infrastructure capable of rapidly building and analysis of mechanistic or hybrid (e.g., combining  
470 ABM and machine learning (38)) models to guide infection control and policymaking under  
471 urgency and sparse data conditions.

## 472 473 474 **Tradeoffs between health and economic impacts of interventions**

475 One of the biggest trade-offs we see in our results is that of cost vs. effectiveness,  
476 particularly with respect to viral testing. Sufficiently intensive testing is highly effective at  
477 controlling transmission, but viral testing can be quite expensive, whether from the cost of test  
478 kits themselves, the cost of increased unavailability due to isolation of individuals who test  
479 positive, or both. Importantly, the intuitive solution of trying to find a moderate level of testing  
480 that optimizes this tradeoff is not necessarily a productive approach—testing, but at an  
481 insufficient frequency to achieve reliable control can actually be more expensive than either more  
482 frequent testing or not testing at all. The level of testing at which this economic “worst of both  
483 worlds” occurs is one of multiple aspects of intervention effects that is heavily dependent on the  
484 level of community transmission (modeled as individual housing that provided opportunity for  
485 acquiring infection within the community), further complicating the effort to select an optimal  
486 approach. It is helpful to realize the multiscale nature of infection control in work environments  
487 deemed essential to society, where the interest is to control the infection and its effects at the  
488 worker individual level (to protect the individual employee's health) and at the worker population  
489 level (to reduce infection spread and cost of control, and increase labor availability). These scale-  
490 related trade-offs spill over into the trade-off between costs of control (borne primarily by the  
491 company) and effectiveness (borne by both the company and individuals), leading to

inefficiencies commonly faced in the private provision of public goods (39). Designing public health policies that align operation incentives with desired public health outcomes is therefore critical to ensure the optimal provision of infection control interventions by operations. This trade-off spills over into a broader challenge around both protecting essential workers and supplying the country with food. Thus, there is a need for more discussion around essential categories of industry and appropriate metrics for evaluating "costs of control".

## Cost-effectiveness of counterfactual interventions

At an individual operation level, FInd CoV Control can be used preemptively to ask questions such as: "Given the characteristics of the workforce and work environment in my operation, if an infected worker enters my facility in the near future, how likely it is that we will experience an outbreak?" "If we have an outbreak, how likely (in terms of the measures of central tendency and variation) are health and economic impacts under different intervention scenarios?" FInd CoV Control evaluates cost-effectiveness of 12 intervention scenarios and a no-intervention scenario. As seen in **Figure 2** and **Figure 3**, even intensification of vaccination in an already moderately vaccinated population can yield modest but meaningful benefits. For proactive control of COVID-19 in the food industry, maintaining a vaccinated and boosted workforce to be prepared for a new outbreak remains a cost-effective intervention (albeit not sufficient to make other interventions unnecessary). Vaccination uptake can be increased by removing convenience and confidence barriers and leveraging workers' motivation to protect self, family, and community (40). Our model findings seem to resonate with perceptions of the food industry's leadership. Certain companies, particularly those in the labor-intensive meatpacking sector, took proactive measures by mandating vaccinations for their workforce (41-43) and prevented risk of infection among employees and potential plant closures that were prevalent at the beginning of the pandemic (44). In situations where vaccine mandates were not in place, other strategies such as physical distancing requirements and quarantines were implemented; however, these interventions were reported to lead to high worker absenteeism and hindered the efficient operation of processing plants (1). Strategies like screenings for disease were valuable in controlling workplace transmission, but also had serious limitations regarding reliability of the results and posed challenges due to being labor-intensive and costly compared to simpler strategies like use of face coverings and practicing personal hygiene (45). These observations in the food industry match the findings in our model about the effectiveness of screening, testing and physical distancing/biosafety strategies in preventing symptomatic cases, albeit with high expenses and production losses associated with testing strategies. Effectiveness can also trade off against "costs" that are not strictly monetary. For example, even very intensive physical distancing and biosafety measures may be cost-effective, but some aspects of such measures (e.g., masking and face shields) can be highly unpopular in the long run (and even limit productivity in harsh work environments, such as extreme cold, hot and wet/damp), especially given the previous observation of the limitations of *reactive* interventions (46). A comparison between the effects of highly and moderately effective interventions in this category supports the idea that, if one is going to implement masking and face shields, the addition of ventilation improvements is likely to be cost-effective. Our model revealed that predictions about intervention effectiveness are highly sensitive to the degree of community transmission. This emphasizes the importance of interpreting effectiveness of work-based interventions in the light of the epidemiology of the disease in the community. This also emphasizes the importance of mitigating disease spread outside of work; however, this is particularly challenging for agricultural worker populations that are not stationary and typically share housing and transportation, allowing for easy employment-related transmission of the virus (47, 48).

542  
543

## Limitations and future directions

544 The empirical support for model parameter values varies, and this is of particular concern  
545 for parameters identified as influential in the Sensitivity analysis (**Figure 6**). One area of  
546 particular concern, given a combination of high sensitivity, moderate support (i.e., a good amount  
547 of data, but somewhat coarse-grained, and with significant potential for confounding), and a  
548 history of changing strains, is the magnitude of long-lasting immunity provided by boosting (e.g.,  
549 parameter  $\phi$ ), revealing that this is a critical knowledge gap requiring further research. Some more  
550 structural limitations to our model include our relatively simple model of change in infectiousness  
551 over the course of infection, our assumption that voluntary self-isolation is rare enough in  
552 essential workers to be omitted from the model, our relatively simple model of vaccination and  
553 boosting interventions (exponential decay of the eligible but unvaccinated/unboosted), and a  
554 simplified binary notion of housing for a given operation as being either shared or individual.  
555 There are numerous possible refinements of this model, many of which are facilitated to a greater  
556 or lesser extent by its modular structure. Three areas seem particularly likely to be fruitful: (i)  
557 Replacement of the current discrete-staged model of infectiousness over time with continuous  
558 infectiousness curves, analogous to the continuous curves that make up aspects of our continuous  
559 immunity trajectories; (ii) Continued improvement of our model of immune effects, immune  
560 boosting, and immune waning, as well as accounting for the changes in vaccination guidelines;  
561 and (iii) Incorporating multiple simultaneous interventions (starting at different times) and  
562 incorporating mixed individual and shared employee housing. More broadly, we hope to further  
563 increase the modularity, flexibility, and ease-of-use of the model, to facilitate easy modification to  
564 address other respiratory pathogens and/or other critical infrastructure sectors to enhance  
565 resilience and responsiveness to similar future outbreak events. Towards these goals, we created a  
566 user-friendly web interface for an early version of FInd CoV Control described in this article,  
567 which allows the user to customize it to the characteristics of their workforce and generate a clear  
568 and easily interpretable confidential result (49).

569  
570  
571

## Materials and Methods

### Employee population module

574 We model a heterogeneous population of agents (employees) with a variety of attributes  
575 reflecting both their current state and certain aspects of their personal history. Agent attributes set  
576 at the simulation start are summarized in **Table 1**. Attributes that represent past events and current  
577 state include age, (directly) immunity-related attributes, vaccination history, and the current state  
578 of infection, if any.

579  
580

#### *Age*

581 Agents are randomly assigned an age category, with probabilities that are derived from  
582 industry-wide data about the age of agricultural workers (50). This age category is then used to  
583 determine their probabilities, in the absence of immunity, of experiencing symptoms or dying  
584 (**Table S1**).

585  
586

#### *Immunity-related attributes*

587 In this model, all of an agent's attributes that are directly relevant to that agent's immunity,  
588 and that are not a consequence of their age, represent acquired immunity (whether complete or  
589 partial) to SARS-CoV-2 infection and COVID-19 disease. These attributes are associated with  
590 specific past events that created or boosted that agent's immunity; for ease of reference, we refer



591 to these simply as *immunity events* (**Table S2**). Thus, all agents had, conceptually speaking, an  
592 immune status of fully Susceptible (S) and a vaccination status of Not Vaccinated (NV, also  
593 referred to as unvaccinated) at the start of the COVID-19 pandemic, but some may have different  
594 values for one or both of these attributes at the start of the *simulation*.

595 Immunity-related attributes include the time ( $t_{last, i}$ ) of the *most recent* immunity event, the  
596 time ( $t_{R, i}$ ) of the most recent recovery from natural infection (if any), an “immunity trajectory”  
597 ( $C_i$ , representing a trajectory defined by a combination of vaccination status and whether the  
598 agent has previously recovered from natural infection), and what the agent’s level of immunity  
599 was immediately prior to their most recent immunity event ( $P_{last, E, i}$ ,  $P_{last, IP, i}$ , and/or  $P_{last, IS, i}$ )  
600 (**Table 1**). Together, these determine an agent's Protection against Any Infection ( $P_{E, i}$ ), Protection  
601 against Symptomatic Infection given Any Infection ( $P_{IP|E, i}$ ), and Protection against Severe  
602 Infection given Symptomatic Infection ( $P_{IS|IP, i}$ ) at the present time (**Table 1** and **Text S3B**). Each  
603 immunity trajectory includes curves for  $P_{E, i}$ ,  $P_{IP|E, i}$ , and  $P_{IS|IP, i}$ . These may include an initial  
604 increase in immunity, referred to as “ramp-up”; an initial period of total immunity; and/or  
605 immune waning. During both ramp-up and immune waning,  $t_{last, i}$  is relevant; during complete  
606 immunity (for immunity trajectories R, HV1, HV2, and HB only),  $t_{R, i}$  is relevant (specifically, in  
607 determining that there *is* complete immunity); and during ramp-up,  $P_{last, E, i}$ ,  $P_{last, IP, i}$ , and/or  
608  $P_{last, IS, i}$  are also relevant. These attributes are discussed further in the section “Immune dynamics”  
609 and in **Text S3B** and **Tables S4-S7**.

610

### 611 ***Vaccination History***

612 We assume for the sake of simplicity that all vaccination and boosting uses the  
613 monovalent Pfizer vaccine. Therefore, vaccination history includes the number of doses of  
614 vaccine the agent has received (i.e., whether they are unvaccinated (NV), partially vaccinated  
615 (V1), fully (primarily) vaccinated (V2), or boosted (B)), and when they received each of their  
616 previous doses, if any (**Figure 1B.iv**). Generally, only the time of their most recent dose is  
617 relevant to the model dynamics (**Table S4**). The current version does not account for repeated  
618 boosting in the vaccination history.

619

### 620 ***State of Infection***

621 An agent's current infection status can be: Not Infected (NI), infected, but not yet  
622 infectious (E, for “Exposed”), Asymptomatically Infectious (IA), Presymptomatically Infectious  
623 (IP), Mildly symptomatic (IM), Severely symptomatic (IS), Critically symptomatic (IC), or Dead  
624 (D) (**Figure 1B.iv**). Additionally, if that state is anything other than Not Infected, we record how  
625 long they have been in that state; together with their precalculated duration (see below) for that  
626 state, this determines how much longer they will remain in it before progressing, recovering, or  
627 dying.

628

### 629 ***Initial setting of agent infection and vaccination history***

630 Agents' history of immunity events prior to the start of simulation is important for  
631 immunity (and immune ramp-up and waning), and their history of vaccination events specifically  
632 is important for their eligibility for future vaccination (both primary and boosting). Therefore,  
633 user input (**Table 2**), is used to determine what fraction of the population has and has not  
634 experienced various immunity events and when. We then randomly generate exact times in a  
635 simple fashion. This aspect of run initialization involves (i) current infection status initialization,  
636 (ii) infection history initialization, and (iii) vaccination history initialization. These aspects do not  
637 directly interact with each other, although infection history and vaccination history interact in  
638 their effects on immunity. The initial settings are described in **Text S2**.

639

640

## 641 Disease transmission module

### 642 *Course of infection*

643 The main aspects of the course(s) of infection are summarized in **Figure 1B.iv**. Agents are  
644 categorized as Not Infected (NI); Exposed (E); Infectious (I); or Dead (D). Infectious agents are  
645 further divided by whether they currently have clinical disease (IA and IP vs. IM, IS, and IC),  
646 whether they will subsequently develop clinical disease (IA vs. IP), and/or how severe their  
647 symptoms are (IM vs. IS vs. IC). They are further categorized by their immunity trajectory – fully  
648 Susceptible (S); one of the Vaccinated trajectories (V1, V2, or B); Recovered (R); or one of the  
649 Hybrid (H) immunity trajectories (HV1, HV2, or HB) – and (for all immunity trajectories other  
650 than S) the times since their last immunity event (their entry or reentry into that immunity  
651 trajectory) and their last recovery, if any (see “Immune dynamics” section).

652 Infectible agents (i.e., agents whose infection status is NI, and whose susceptibility to  
653 infection (see “Transmission model” section) is greater than 0) can acquire infection with SARS-  
654 CoV-2 from a potentially infectious contact with an Infectious agent (i.e., IA, IP, IM, IS, or IC).  
655 The probability of such a contact resulting in an infection depends on the susceptibility to  
656 infection of the infectible agent ( $1 - P_{E,i}$ ) and the infectiousness of the infectious agent ( $\beta_{IA}$ ,  $\beta_{IP}$ ,  
657 or  $\beta_{IM}$ ). How contacts are made is described in the “Work environment module” section.

658 Upon infection, the formerly infectible agent enters the Exposed state (E), and after a  
659 period of time ( $D_{E,i}$ ), the Exposed agent becomes infectious (I). At this time, they enter one of  
660 two states, both of which are continuously infectious, but without clinical disease: either IA or IP,  
661 the latter of which is the first stage of the symptomatic path. The distinction between IP and IA  
662 reflects a substantial difference in per-contact transmission rates between the two (51).

663 All IA agents are assumed to recover following a period of time ( $D_{IA,i}$ ). Agents taking the  
664 symptomatic path progress through up to four stages: IP, IM, IS, and/or IC. All IP agents progress  
665 to the IM state after a period of time ( $D_{IP,i}$ ), but agents who are in IM, IS, or IC may, after the  
666 corresponding period of time ( $D_{IM,i}$ ,  $D_{IS,i}$ , or  $D_{IC,i}$ , respectively), either continue their disease  
667 progression to the next state on the symptomatic path or recover.

668 When an agent recovers, regardless of which infectious state they recovered from, their  
669 last immunity event time ( $t_{last,i}$ ) and Recovered immunity event time ( $t_{R,i}$ ) are both set equal to the  
670 current time, their infection status is set to NI, and their immune status is set to Recovered (R) if  
671 they have never been vaccinated (NV), or to the appropriate Hybrid state (HV1, HV2, or HB)  
672 otherwise. For agents in IC that do not recover, the next step is Death (D).

673 We do not explicitly model individual symptoms such as fever, cough, etc. However, for  
674 the temperature testing intervention, we do tacitly assume that fever is only present if the  
675 individual is symptomatically infected (IM, IS, or IC). We define “Severe” symptoms as those  
676 requiring hospitalization; consequently, we assume that only agents with an infection status of IA,  
677 IP or IM can transmit to their fellow employees, because agents with Severe or Critical symptoms  
678 are so sick that they require hospitalization. Relative transmissibility (per contact) is set based on  
679 the infection stage (**Table S3**). *Absolute* transmissibility has no effect in the model, as we set the  
680 average expected contact rate in order to achieve a specified basic reproduction number ( $R_0$ ), and  
681 our assumptions about contacts per day (**Text S3A**) make the distinction between twice as high  
682 transmissibility per contact and twice as many expected contacts mathematically irrelevant.

683  
684 For agents in any of the infected states, disease progression is based on the duration of each state  
685 (**Table 4**), age-dependent baseline probabilities of entering each disease state during disease  
686 progression (**Table S1**), and immunity-dependent modification of those baseline probabilities.

### 688 *Transmission model*

689 Agents who are infectible (i.e., agents whose infection status is NI, and whose  
690 susceptibility to infection is greater than 0) can be infected by contacts with either infectious

691 coworkers or infectious people outside of work, in the broader community (if housing is  
692 “individual”). Contact structures of the agents while at work were determined by the place of  
693 agents in the hierarchical structure of the farm or facility and their work schedule. To be more  
694 precise, for each shift type (e.g., weekday Production Shift 1, weekend Cleaning Shift, etc.), we  
695 have a matrix of expected contact rates between pairs of agents. For some combinations of a pair  
696 of agents and a shift type, a non-zero contact rate may represent contacts made at work; for  
697 others, it may represent contacts made in shared housing. Further details are in **Text S3A**.

### 698 **Immune dynamics**

699 We distinguish between 8 basic states (immunity trajectories) with respect to immunity:  
700 fully Susceptible (S), partially vaccinated (i.e., with one dose of a two-dose primary series) (V1),  
701 Fully Vaccinated (for the purpose of this study defined as a 2-dose primary series; V2), Boosted  
702 (B), Recovered (R), and Hybrid immunity (H) with partial vaccination (HV1), with full  
703 vaccination (HV2), or with full vaccination and a Booster (HB). Non-hybrid vaccinated  
704 trajectories (V1, V2, and B) feature a smooth ramp-up from their individual’s previous level of  
705 immunity, that lasts for  $T_{V1 \rightarrow V2} = 21$  days,  $T_{\text{ramp}, V2} = 14$  days, or  $T_{\text{ramp}, B, 1} + T_{\text{ramp}, B, 2} = 14$  days,  
706 respectively, counting from the time since the individual’s last immunity event (i.e., first vaccine  
707 dose, second vaccine dose, or booster shot, respectively). The non-hybrid Recovered trajectory  
708 (R) features an initial  $T_{\text{total}, R} = \text{two months (61 days)}$  period of total immunity, counting from the  
709 time of their (most recent) recovery. The Hybrid immunity trajectories (HV1, HV2, and HB)  
710 have characteristics of both vaccinated and recovered trajectories, and can be entered either by  
711 recovery following vaccination or by vaccination following recovery. Consequently, a particular  
712 individual’s experience of one of these trajectories may include either or both of total immunity  
713 and ramp-up. The transitions between these immunity trajectories are summarized in **Table S2**,  
714 and the equations for the protection that they offer are given in **Table S7**. As evidence has  
715 mounted that waning immunity, both from natural infection and from vaccination, plays an  
716 important role in the dynamics of transmission during the pandemic, we included this in our  
717 model. To take full advantage of the agent-based nature of our model, we assigned each agent  
718 three variables indicating the major factors influencing their level of susceptibility to both  
719 infection and progression: (i) the immune state that they entered at the time of their *last immunity*  
720 *event*, (ii) the time at which that event occurred (and hence, at any given subsequent point in time,  
721 how long it has been since that event), and (iii) the time of their *last recovery* from natural  
722 infection. The exceptions are agents whose immune state is fully Susceptible (S), whose time of  
723 last event is not defined, and agents whose immune state is either fully Susceptible (S) or one of  
724 the non-hybrid Vaccinated states (V1, V2, and B), whose time of last recovery is not defined. We  
725 then created functions (**Table S7**) giving, for any valid combination of state, time since entry, and  
726 time since recovery (and previous immunity, if they are currently in a ramp-up period), their level  
727 of relative protection from each of infection, symptomatic infection conditional on any infection,  
728 and severe infection conditional on symptomatic infection. We used exponential or exponential-  
729 mixture waning for long-term behavior of V2 and B (fitted from data in (52)), and logistic waning  
730 for long-term behavior of R, HV1, HV2, and HB (with parameters inferred from the tables in  
731 (53)), with some special case behavior at the start of states other than S (ramp-up and/or a period  
732 of complete immunity), in order to account for the delay in reaching full protection following  
733 vaccination, and to prevent unrealistic cycles of extremely rapid reinfection. This is further  
734 explained in **Text S3B**.

### 735 **General model of vaccination**

736 Agents’ vaccination status can be unvaccinated (NV), partially vaccinated (V1), fully  
737 vaccinated (V2), or boosted (B). This vaccination status directly corresponds to their immune  
738 status (with NV corresponding to fully Susceptible (S)) if they have never recovered from a  
739  
740

741 natural infection; if they have, then their immune status is either Recovered (R), if they have  
742 never been vaccinated, or one of the Hybrid immunity trajectories (HV1, HV2, and HB).

### 743 **Vaccination trajectories**

744 Partially vaccinated agents become eligible to receive a second shot  $T_{V1 \rightarrow V2} = 21$  days  
745 after receiving their first one, and fully vaccinated agents become eligible to receive a booster  
746 shot  $T_{V2 \rightarrow B} = 5$  months (treated as a deterministic 152 days) after their second shot (54). We  
747 assume that all V1 agents enter V2 states as soon as they are eligible, but that only a fraction of  
748 V2 agents enters the B state as soon as they are eligible. We further assume that agents who are  
749 eligible to become V1/B at simulation start, but have not yet done so, will not become V1/B  
750 (respectively) during the simulation, in the absence of an intervention to promote primary  
751 vaccination/boosting, respectively.

### 752 **Work environment module**

753  
754  
755 In both farm and facility models, each week consists of 5 work days and 2 non-working  
756 days (i.e., a typical "work week" and weekend in the US). Each calendar day is modeled as  
757 consisting of 3 eight-hour periods we call "shifts." Each agent spends two shifts awake, and one  
758 asleep. For simplicity, we tie the agent's sleep cycle to their work cycle, so that each agent spends  
759 their first shift awake at work if it's a work day. This structure is illustrated for a sample agent  
760 (one scheduled to work on the first shift of the calendar day) in **Figure 1B.i** and shown in greater  
761 detail in **Table S8**.

762  
763 In the facility model, each working day consists of Production Shift 1, Production Shift 2  
764 (which may actually be a non-working shift, if the facility in question only has one production  
765 shift per day), and a Cleaning Shift. In the farm model, all agents are scheduled to work on the  
766 same shift, which, by analogy with the facility model, we refer to as Production Shift 1. (Hence,  
767 by the same analogy, all agents are awake, but not working, during Production Shift 2, and asleep  
768 during the shift that would be the "Cleaning Shift" in the facility model.)

769 We distinguish between available and unavailable agents for the purposes of SARS-CoV-  
770 2 transmission between agents. Available agents are available to work their scheduled shifts –  
771 meaning that they can do work (relevant in the economic analyses), and can also potentially  
772 infect, or be infected by, other agents. Agents are available by default, but may become  
773 unavailable to work (and, subsequently, may become available again).

774 In the baseline (no intervention) model, unavailable agents are limited to those who are  
775 either hospitalized (i.e., those who have an infection status of IS or IC) or dead (those who have  
776 an infection state of D). Hospitalized agents become available again upon recovery. Under certain  
777 interventions, agents who are not hospitalized may become diagnosed and isolated; these remain  
778 unavailable until they are deisolated (**Text S3C**).

779 We model a facility or farm with a hierarchical organization, although the details of this  
780 hierarchy differ somewhat between the facility model and the farm model. This hierarchy is  
781 assumed to be fixed over the time horizon of the model, as is the associated work schedule. The  
782 expected number of contacts between pairs of workers who are both "available" (i.e., not isolated,  
783 hospitalized, or dead) is likewise held constant (i.e., we do not reassign workers between work  
784 crews or production lines based on other workers' absences). To make the interface more  
785 manageable, we assume that the structure of the operation is "regular" in the sense that if there are  
786 two or more of the same sub-structure (e.g., two production shifts, two or more teams of work  
787 crews, two or more work crews within a team, or two or more production lines), then each of  
788 those sub-structures has the same structural characteristics (e.g., if one work crew consists of 10  
789 workers and a foreman, then all work crews consist of 10 workers and a foreman).



790 Features specific to the farm and facility models are described in **Text S4A** and **S4B**.

791 Briefly, we assume the following:

- 792 • All workers live in the same type of housing (i.e., either individual or employer-provided  
793 shared housing).
- 794 • All workers work a regular 40-hour, 5-day work week (8-hour shifts) and 2-day weekend,  
795 with the model simulation starting on a random day of the week, except for a small number of  
796 floating workers (e.g., quality assurance technician, mechanic) in the facility model, for whom  
797 the work shift(s) on a given day is/are randomly selected.
- 798 • There are many more contacts within the hierarchical structure than outside it (e.g., more  
799 contacts between workers on the same crew/production line than between workers on  
800 different crews/production lines, more contacts between foremen and supervisors than  
801 between other workers and supervisors, etc.), but that contacts are possible between any two  
802 agents who are both present on the same shift.
- 803 • All contact between workers occurs either (a) while traveling to, at, or traveling home from  
804 work, or (b) in shared, employer-provided housing, i.e., that workers in individual housing do  
805 not socialize with each other outside of work.
- 806 • There is homogeneous mixing within employer-provided housing.
- 807 • Worker contacts on the way to and from work follow the same basic patterns as worker  
808 contacts at work (e.g., we tacitly assume that shared transportation is substantially more likely  
809 to group together workers who are on the same crew than workers who are on different  
810 crews).

## 813 **Interventions**

814 Apart from the baseline (non-) intervention, we modeled 12 interventions falling into four  
815 groups (described in detail in **Text S3C**):

- 816 • “Temperature screening” (1 scenario) denotes temperature screening and isolation where  
817 all employees arriving for their shift are tested prior to admitting employees to work for  
818 that shift. The temperature threshold is set at 38°C.
- 819 • “Virus test” (3 scenarios) denotes low-, moderate-, and high-intensity of viral testing and  
820 isolation, respectively modeled with the probability  $p = 5, 30,$  or 100% of each employee  
821 being tested each shift upon arrival at the workplace.
- 822 • “Vaccine” (5 scenarios) denotes primary “vaccination” of unvaccinated workers with 2  
823 doses at a daily probability of  $p = 2$  or 4%; “boosting” of boosting-eligible but unboosted  
824 workers at  $p = 2$  or 4% per day; or a combination of both primary and boosting vaccination  
825 interventions (“vax+boosting”) at  $p = 2\%$  per day.
- 826 • “Physical distancing/Biosafety” (3 scenarios) where physical distancing and/or biosafety  
827 interventions are modeled as generating a 20, 40, or 80% reduction in  $R_0$  at work (i.e., -20,  
828 -40 or -80%  $R_0$ ), such as through the application of masks, face shields, physical barriers,  
829 and/or ventilation. The exact approach necessary to achieve these desired effects on  $R_0$   
830 will vary across work environments. However, to illustrate how higher-effectiveness  
831 interventions may be built by “stacking” multiple lower-effectiveness strategies and to be  
832 able to quantify their net cost in the subsequent economic analysis, in absence of required  
833 data we assumed: (i) For a low-effectiveness (-20%  $R_0$ ) intervention, the use of KN95  
834 masks, one per employee per shift; (ii) For a moderate-effectiveness (-40%  $R_0$ )  
835 intervention, a low-effectiveness intervention combined with the use of face shields, one  
836 per employee per 30 days; (iii) For a high-effectiveness (-80%  $R_0$ ) intervention, a  
837 moderate-effectiveness intervention combined with ventilation improvement, such as with  
838 the use of (a) portable air cleaner(s).

839 We performed counterfactual comparisons of the no-intervention baseline and 12  
840 interventions (**Figure 1A**). To make these comparisons more precise, on a run-by-run basis, we  
841 (a) reseed the pseudorandom number generator (pRNG) with the same value before processing  
842 each intervention and (b) make use of the pRNG in such a way as to ensure that two runs that start  
843 with the same pRNG state and that differ only in the factors that we allow to vary between  
844 possible interventions under a given scenario, will have the same pRNG state at all analogous  
845 points thereafter.

## 847 **Model running**

849 For each run, the model is first initialized. Then, at each time step, the following processes  
850 occur:

- 851 • Agents eligible for deisolation (**Text S3C**) are deisolated.
- 852 • If any testing is being performed (**Text S3C**), agents who are scheduled to work and  
853 (potentially) available are tested.
  - 854 ○ If the testing probability per shift is 1, then all (potentially) available agents are tested.
  - 855 ○ If the testing probability per shift is  $< 1$ , then the number of tests to be performed is  
856 determined, and these are performed on the (potentially) available agents in order from  
857 least to most recently tested, randomizing ties.
  - 858 ○ If any agents test positive, they are isolated, and their isolation time is set to the  
859 present time.
- 860 • Agents to be vaccinated are randomly selected (meaning that they are not infected and  
861 either they have just become eligible for a booster and are boosting on time, or they are  
862 eligible to receive some form of vaccine, and there is a vaccination-promoting  
863 intervention), and their immunity event times, immunity trajectories, and vaccination  
864 statuses are updated accordingly.
- 865 • Transmission (potentially) occurs, with probabilities as described in **Text S3A**.
- 866 • Infected agents who are eligible to leave their current state of infection (i.e., the sum of  
867 their time of entering that state and their precalculated duration for that state is less than  
868 the time at which the current time step ends) do so, randomly selecting which new  
869 infection state to enter, if necessary, as described above.
  - 870 ○ This step is repeated as necessary, i.e., an agent may in principle progress twice in a  
871 single time step if the duration of one of their infection states is sufficiently small.
  - 872 ○ If an agent recovers, their last recovery and last immunity event times ( $t_{R, i}$  and  $t_{last, i}$ )  
873 are set to the present time, and their immunity trajectory is updated.
- 874 • Outcomes are recorded for use in subsequent analysis.

875 The ABM model and all analyses were implemented in R software (version 4.0.4) (58).

## 877 **Model outcomes**

879 Our outcomes of interest can be broadly grouped into those which pertain primarily to  
880 public health, and those which pertain primarily to business disruptions and economic impact. We  
881 compare these outcomes both across (potential) interventions within a setting scenario and across  
882 different scenarios.

### 883 **Public health outcomes**

885 Our primary public health outcome of interest is the total number of symptomatic SARS-  
886 CoV-2 infections that occur across the course of a run. We define this as the number of occasions  
887 of an agent transitioning from the IP to IM state between the start of simulation ( $t = 0$ ) and the end

888 of simulation ( $t = T$ ). This includes transitions into IM of agents who were in the E state at  
889 simulation start, if they transition from E to IP (and, subsequently, to IM) rather than to IA, but  
890 does not include the transitions into IM *before*  $t = 0$  for agents that were in IM at simulation start.  
891 It also does not include the transitions into IM *after*  $t = T$  of any agents who are in E or IP at  
892 simulation end. If the simulation length and transmission dynamics are such as to result in some  
893 agents transitioning into IM more than once during the simulation, then we count each such  
894 transition separately; hence, it may be possible, depending on user-set parameters, to have a  
895 number of symptomatic infections that exceeds the number of agents. An additional outcome of  
896 interest is the number of total SARS-CoV-2 infections (i.e., including asymptomatic infections)  
897 that occur across the course of a run. We present public health outcomes, for each intervention, as  
898 a curve of the mean over time, as well as violin plots summarizing the cumulative distribution  
899 over a defined planning horizon, to allow both comparison of expectations and understanding of  
900 the variance.

901

### 902 *Economics outcomes*

903 The main dimensions considered for economic analysis are: (i) direct costs of performing  
904 an intervention, and (ii) the productivity costs or benefits of the intervention. To assess (i), we add  
905 certain details to our hypothetical interventions, based on how interventions are implemented in  
906 real life. Relative to a "no-intervention" baseline of doing nothing, the direct costs of interventions  
907 can be expected to always be greater than or equal to zero. Each intervention is compared to the  
908 baseline to estimate direct costs of performing each intervention. Calculations of the costs of  
909 interventions are described in **Text S5**. To answer (ii), we estimate the productivity loss based on  
910 the worker absences from the infection model with a Cobb-Douglass production model. The  
911 Cobb-Douglass production function takes the general form

$$912 \quad Q = AL^\beta K^\alpha$$

913 where operations use labor  $L$  and capital  $K$  to produce output  $Q$ , and  $A$  is some constant. The  
914 output elasticities of labor and physical capital are  $\beta$  and  $\alpha$ , respectively. In choosing output level  
915  $Q$ , operations face the following cost function (abstracting from fixed costs):

$$916 \quad C = wL + rK$$

917 where  $w$  is the wage rate and  $r$  is the rental rate for capital. Profit-maximizing operations operate  
918 at the efficient production frontier in equilibrium.

919 Based on a previous survey of producers (17), one important assumption made in the  
920 model is that the facility can maintain full production ( $Q_f$ ) with up to 15% of absenteeism without  
921 incurring appreciably higher production costs. If a operation can reduce its "full output" labor  
922 input allocation  $L_f$  to a short-staffed model where  $L_s = 0.85L_f$  without reducing full output  
923 ( $Q_s = Q_f$ ) in a costless way, the operation must be able to substitute enough additional capital  
924 above the current "full output" allocation in the short run, such that the cost of increased capital is  
925 completely offset by reduced labor costs. To capture this short-run flexibility, we therefore  
926 assume that the current equilibrium is not unique, but instead one in a set of cost-minimizing  
927 equilibria where  $0.85L_f \leq L \leq L_f$ .

928 If labor absenteeism exceeds 15%, however, we assume that the capital allocation now  
929 remains fixed at the (higher) 15% absenteeism point, and the production paradigm takes the  
930 previously described Cobb-Douglass form. Under that framework, since operations cannot  
931 substitute capital for labor, they will have to reduce output based on these labor shortages. In an  
932 empirical work application of productivity analysis in the food and agricultural sector in the US,  
933 Ahmad (59) estimates a Bayesian stochastic Cobb-Douglas production function using US state-  
934 level agricultural data from 1960-2004 ( $n=2,160$ ). He estimates  $\alpha = 0.316$  [0.271, 0.362] and  $\beta =$   
935 0.437 [0.392, 0.483]. Thus, production is

$$Q(L) = \begin{cases} Q(L_f) & , \quad \frac{L}{L_f} \geq 0.85 \\ Q(L_f) \left( \frac{L}{0.85L_f} \right)^{0.437} & , \quad \frac{L}{L_f} < 0.85 \end{cases}$$

Full production quantity is provided by the users, and estimated production loss is simply

$$Q(L_f) - Q(L) = \begin{cases} 0 & , \quad \frac{L}{L_f} \geq 0.85 \\ Q(L_f) \left( 1 - \left( \frac{L}{0.85L_f} \right)^{0.437} \right) & , \quad \frac{L}{L_f} < 0.85 \end{cases}$$

The results of the above analyses are summarized by the following economic outcomes: the mean number of employees unavailable to work production shifts over time; violin plots summarizing the distribution of the cumulative number of production worker-shifts missed; fraction of shifts short; and total direct expenses, production losses, and total costs associated with an intervention (US\$).

### Scenario analysis

We tested scenarios corresponding to factors: “setting” (“farm” vs. “facility”), “housing” (“individual” vs. “shared”), “vaccinated” (“high” vs. “none”), and “recovered” (“high” vs. “nothing”). In a full factorial analysis approach, we tested all 16 combinations of these four factors and for each scenario we ran the no-intervention baseline and all 12 interventions. We then constructed regression trees, using the R package rpart (version 4.1.19; using default values for all control parameters) for each of our three primary outcomes (symptomatic infections, worker-shifts unavailable, and total cost) and the two separate contributors to total cost (production losses and intervention expenses) vs. the four scenario parameters and the 5 intervention parameters defining our 12 interventions (**Table S13**). In the main text of this paper, we only present a subset of results for which setting is “facility,” for reasons discussed in the “Scenario analysis” subsection of the Results section.

### Sensitivity analysis

We evaluated the parameter sensitivity for four outcomes using the OFAT approach. Three outcomes were the total symptomatic infections, total number of worker-shifts missed and total cost over the simulation length. The fourth outcome was the effective reproduction number ( $R_{eff}$ ) at the start of simulation. Because of the large number of parameters to be examined, under (initially) a variety of scenarios, we averaged results over batches of 100 runs each, rather than the 1000 runs that we use in most other contexts. In general, for a given parameter whose value in our model was  $x$ , we examined results when that parameter was set to  $1/2 x$ ,  $x$ , and  $2x$  (**Table S14**). For 2 parameters ( $T_{V2 \rightarrow B}$  and  $T_{1st V2 \rightarrow 0}$ ), one of these values was impossible, given a requirement that it be possible for some individuals to be eligible for boosting at simulation start. For these parameters, we set the relevant value to the most extreme possible value in the same direction (i.e., 212.5 days for (increased)  $T_{V2 \rightarrow B}$  and 305 days for (reduced)  $T_{1st V2 \rightarrow 0}$ ).

In order to estimate  $R_{eff}$  at the start of simulation (other outcomes were measured without this modification), we modified the model so that, when an employee was infected, instead of their infection status being changed from Not Infected to Exposed, their immunity was set to Recovered, and their  $t_{last, i}$  was reset to the current time. Conceptually, this amounts to their “skipping over” any infected states, and going directly from infection to recovery. This ensured that all employee-to-employee transmissions would necessarily be from employees who were



980 infected at the start of simulation. We then ran the model starting with a single Exposed employee  
981 (as is the default), and observed the number of employee-to-employee transmissions that  
982 occurred. The average of that number across multiple runs was then used as an empirical estimate  
983 of  $R_{eff}$ . In scenarios with “individual” housing, the community-acquired infection was allowed to  
984 occur (likewise transferring infected employees directly into a Recovered state, meaning that they  
985 were not immediately infectible by the index case), but was not included in the count of  
986 employee-to-employee transmissions measured by  $R_{eff}$ .

987 We initially examined the results of sensitivity analysis, using default user-settable  
988 parameters, except as noted, across the same range of settings as we initially considered for  
989 scenario analysis. We found that, for most parameters, sensitivity was higher in “high” settings  
990 (i.e., with a history of both vaccination and recovery from natural infection) than in historical or  
991 pseudo-historical settings, higher in facility settings than in farm settings, and higher in settings  
992 with shared housing than in settings with individual housing. For this reason, we focused our  
993 further examination on a setting of a facility, with all parameters default except for housing,  
994 which was “shared” instead of “individual” (with physical distancing in shared housing at the  
995 default level). Looking back at scenario analysis, this is equivalent to the scenario in which both  
996 “vaccination” and “recovered” were “high.”

997 For each parameter-intervention-outcome combination, we obtained three mean outcome  
998 values, as described above. We divided the largest of those three values by the smallest to obtain a  
999 simple measure  $\omega$  of the sensitivity that could address both monotonic and non-monotonic effects.  
1000 For each parameter, we then chose the largest such measure ( $\omega_{max}$ ) across all intervention-  
1001 outcome combinations. We then selected for depiction and discussion in the Results section those  
1002 parameters for which  $\omega_{max} \geq 2$  (all results are shown in **Figures S5-S8**). As the only exception to  
1003 this process, we omitted the baseline no-intervention scenario in the Total Cost outcome, as the  
1004 sensitivity measure for this outcome-intervention was generally undefined or (rarely, and  
1005 seemingly at random) infinite, due to the extreme rarity of non-zero Total Cost at baseline.

## 1006 1007 1008 **References**

- 1009 1. J. Luckstead, R. M. Nayga Jr., H. A. Snell, Labor issues in the food supply chain amid the  
1010 COVID-19 pandemic. *Appl. Econ. Perspect. Policy*. **43**, 382-400 (2021).
- 1011 2. National Conference of State Legislatures, (NCSL), “COVID-19: Essential workers in the  
1012 States” (2021, [www.ncsl.org/labor-and-employment/covid-19-essential-workers-in-the-](http://www.ncsl.org/labor-and-employment/covid-19-essential-workers-in-the-states#Map)  
1013 [states#Map](http://www.ncsl.org/labor-and-employment/covid-19-essential-workers-in-the-states#Map)).
- 1014 3. D. Laborde, W. Martin, J. Swinnen, R. Vos, COVID-19 risks to global food security. *Science*  
1015 **369**, 500-502 (2020).
- 1016 4. J. N. Marchant-Forde, L. A. Boyle, COVID-19 effects on livestock production: A one welfare  
1017 issue. *Front. Vet. Sci.* **7**, 585787 (2020).
- 1018 5. D. Peel, Beef supply chains and the impact of the COVID-19 pandemic in the United States,  
1019 *Anim. Front.* **11**, 33–38 (2021).
- 1020 6. US Department of Agriculture, Economic Research Service, (USDA ERS). 2023. “Farm  
1021 Sector Income During the Pandemic” November 30, 2023. [https://www.ers.usda.gov/covid-](https://www.ers.usda.gov/covid-19/farms-and-farm-households/#income)  
1022 [19/farms-and-farm-households/#income](https://www.ers.usda.gov/covid-19/farms-and-farm-households/#income).
- 1023 7. A. Weersink, A. M. von Massow, N. Bannon, J. Ifft, J. Maples, K. McEwan, M. G. S.  
1024 McKendree, C. Nicholson, A. Novakovic, A. Rangarajan, T. Richards, B. Rickard, J. Rude,  
1025 M. Schipanski, G. Schnitkey, L. Schulz, D. Schuurman, K. Schwartzkopf-Genswein, M.  
1026 Stephenson, J. Thompson, K. Wood, COVID-19 and the agri-food system in the United States  
1027 and Canada. *Agric. Syst.* **188**, 103039 (2021).

- 1028 8. L. Douglas. 2021. “Mapping Covid-19 Outbreaks in the food system.” Food & Environment  
1029 Reporting Network, July 26, 2023. [https://thefern.org/2020/04/mapping-covid-19-in-meat-](https://thefern.org/2020/04/mapping-covid-19-in-meat-and-food-processing-plants/)  
1030 [and-food-processing-plants/](https://thefern.org/2020/04/mapping-covid-19-in-meat-and-food-processing-plants/).
- 1031 9. M. A. Waltenburg, C. E. Rose, T. Victoroff, M. Butterfield, J. A. Dillaha, A. Heinzerling, M.  
1032 Chuey, M. Fierro, R. H. Jervis, K. M. Fedak, A. Leapley, J. A. Gabel, A. Feldpausch, E. M.  
1033 Dunne, C. Austin, C. S. Pedati, F. S. Ahmed, S. Tubach, C. Rhea, J. Tonzel, A. Krueger, D.  
1034 A. Crum, J. Vostok, M. J. Moore, H. Kempfer, J. Scheftel, G. Turabelidze, D. Stover, M.  
1035 Donahue, D. Thomas, K. Edge, B. Gutierrez, E. Berl, M. McLafferty, K. E. Kline, N. Martz,  
1036 J. C. Rajotte, E. Julian, A. Diedhiou, R. Radcliffe, J. L. Clayton, D. Ortbahn, J. Cummins, B.  
1037 Barbeau, S. Carpenter, J. C. Pringle, J. Murphy, B. Darby, N. R. Graff, T. K. H. Dostal, I. W.  
1038 Pray, C. Tillman, D. A. Rose, M. A. Honein, Coronavirus disease among workers in food  
1039 processing, food manufacturing, and agriculture workplaces. *Emerg. Infect. Dis.* **27**, 243-249  
1040 (2021).
- 1041 10. C. A. Taylor, C. Boulos, D. Almond, livestock plants and COVID-19 transmission. *PNAS*  
1042 **117**, 31706-31715 (2020).
- 1043 11. T. L. Saitone, K. Aleks Schaefer, D. P. Scheitrum, COVID-19 morbidity and mortality in U.S.  
1044 meatpacking counties. *Food Policy*, **101**, 102072 (2021).
- 1045 12. Z. Chen, E. Bulut, A. Trmčić, R. Ivanek, Rapid review of government issued documents  
1046 relevant to mitigation of COVID-19 in the U.S. food manufacturing and processing industry.  
1047 *Food Prot. Trends*. **42**, 426–438 (2022).
- 1048 13. A. Trmčić, E. Demmings, K. Kniel, M. Wiedmann, S. Alcaine, Food safety and employee  
1049 health implications of COVID-19: A review. *J. Food. Prot.* **84**, 1973-1989 (2021).
- 1050 14. D. J. Hayes, L. L. Schulz, C. E. Hart, K. L. Jacobs, A descriptive analysis of the COVID-19  
1051 impacts on U.S. pork, turkey, and egg markets. *Agribusiness (N Y N Y)* **37**, 122-141 (2021).
- 1052 15. P. K. Henneberger, J. M. Cox-Ganser, G. M. Guthrie, C. P. Groth, Estimates of COVID-19  
1053 vaccine uptake in major occupational groups and detailed occupational categories in the  
1054 United States, April-May 2021. *Am. J. Ind. Med.* **65**, 525-536 (2022).
- 1055 16. I. T. Agaku, C. Adeoye, T. G. Long, Geographic, Occupational, and sociodemographic  
1056 variations in uptake of COVID-19 booster doses among fully vaccinated US adults, December  
1057 1, 2021, to January 10, 2022. *JAMA Netw Open.* **5**, e2227680 (2022).
- 1058 17. S. Llanos-Soto, E. Bulut, S. I. Murphy, C. J. Henry, C. Zoellner, M. Wiedmann, D.  
1059 Wetherington, A. Adalja, S. D. Alcaine, R. Ivanek, Survey of implemented mitigation  
1060 strategies and further needs of the U.S. food industry to control COVID-19 in the work  
1061 environment in early 2021. *Food Prot. Trends*. **43**, 40-60 (2023).
- 1062 18. S. Vecherin, D. Chang, E. Wells, B. Trump, A. Meyer, J. Desmond, K. Dunn, M. Kitsak, I.  
1063 Linkov, Assessment of the COVID-19 infection risk at a workplace through stochastic  
1064 microexposure modeling. *J. Expo. Sci. Environ. Epidemiol.* **32**, 712-719 (2022).
- 1065 19. P. C. L. Silva, P. V. C. Batista, H. S. Lima, M. A. Alves, F. G. Guimarães, R. C. P. Silva,  
1066 COVID-ABS: An agent-based model of COVID-19 epidemic to simulate health and  
1067 economic effects of social distancing interventions. *Chaos. Solitons Fractals* **139**, 110088  
1068 (2020).
- 1069 20. E. Cuevas, An agent-based model to evaluate the COVID-19 transmission risks in facilities.  
1070 *Comput. Biol. Med.* **121**, 103827 (2020).
- 1071 21. N. M. Ferguson, D. Laydon, G. Nedjati-Gilani, N. Imai, K. Ainslie, M. Baguelin, S. Bhatia,  
1072 A. Boonyasiri, Z. Cucunubá, G. Cuomo-Dannenburg, A. Dighe, I. Dorigatti, H. Fu, K.  
1073 Gaythorpe, W. Green, A. Hamlet, W. Hinsley, L. C Okell, S. van Elsland, H. Thompson, R.  
1074 Verity, E. Volz, H. Wang, Y. Wang, P. G. T. Walker, C. Walters, P. Winskill, C. Whittaker,  
1075 C. A Donnelly, S. Riley, A. C. Ghani, “Report 9 - Impact of non-pharmaceutical interventions  
1076 (NPIs) to reduce COVID-19 mortality and healthcare demand” (WHO Collaborating Centre  
1077 for Infectious Disease Modelling; MRC Centre for Global Infectious Disease Analysis; Abdul

- 1078 Latif Jameel Institute for Disease and Emergency Analytics; Imperial College London, 2020;  
1079 [www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-](http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-on-covid-19/)  
1080 [on-covid-19/](http://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-9-impact-of-npis-on-covid-19/)).
- 1081 22. M. D'Orazio, G. Bernardini, E. Quagliarini, A probabilistic model to evaluate the  
1082 effectiveness of main solutions to COVID-19 spreading in university buildings according to  
1083 proximity and time-based consolidated criteria. *Builde. Simul.* **14**, 1795–1809 (2021).
- 1084 23. E. Okafor, B. Bass, “Modelling the spread of Covid-19 in a typical oil and gas facility setting”  
1085 (SPE Nigeria Annual International Conference and Exhibition, 2021).
- 1086 24. H. Inoue, Y. Todo, The propagation of economic impacts through supply chains: The case of  
1087 a mega-city lockdown to prevent the spread of COVID-19. *PLoS One* **15**, e0239251 (2020).
- 1088 25. F. Dignum, V. Dignum, P. Davidsson, A. Ghorbani, M. van der Hurk, M. Jensen, C.  
1089 Kammler, F. Lorig, L. G. Ludescher, A. Melchior, R. Mellema, C. Pastrav, L. Vanhee, H.  
1090 Verhagen, Analysing the combined health, social and economic impacts of the coronavirus  
1091 pandemic using agent-based social simulation. *Minds Mach. (Dordr)*. **30**, 177-194 (2020).
- 1092 26. S. L. Chang, N. Harding, C. Zachreson, O. M. Cliff, M. Prokopenko, Modelling transmission  
1093 and control of the COVID-19 pandemic in Australia. *Nat. Commun.* **11**, 5710 (2020).
- 1094 27. J. Dehning, J. Zierenberg, F. P. Spitzner, M. Wibral, J. P. Neto, M. Wilczek, V. Priesemann,  
1095 Inferring change points in the spread of COVID-19 reveals the effectiveness of interventions.  
1096 *Science* **369**, eabb9789 (2020).
- 1097 28. A. R. Tuite, D. N. Fisman, A. L. Greer, Mathematical modelling of COVID-19 transmission  
1098 and mitigation strategies in the population of Ontario, Canada. *CMAJ* **192**, E497-E505 (2020).
- 1099 29. J. Lou, S. Borjigin, C. Tang, Y. Saadat, M. Hu, D. A. Niemeier, Facility design and worker  
1100 justice: COVID-19 transmission in meatpacking plants, *Am. J. Ind. Med.* **66**, 713-727 (2023).
- 1101 30. M. Pangallo, A. Aleta, R. M. del Rio-Chanona, A. Pichler, D. Martín-Corral, M. Chinazzi, F.  
1102 Lafond, M. Ajelli, E. Moro, Y. Moreno, A. Vespignani, J. D. Farmer, The unequal effects of  
1103 the health–economy trade-off during the COVID-19 pandemic, *Nat. Hum. Behav.* **8**, 264–275  
1104 (2024).
- 1105 31. Z. Du, A. Pandey, Y. Bai, M. C. Fitzpatrick, M. Chinazzi, A. Pastore y Piontti, M. Lachmann,  
1106 A. Vespignani, B. J. Cowling, A. P. Galvani, L. A. Meyers, Comparative cost-effectiveness of  
1107 SARS-CoV-2 testing strategies in the USA: A modelling study. *Lancet Public Health* **6**, e184-  
1108 e191 (2021).
- 1109 32. The U. S. Census Bureau. 2022. “United States” March 21, 2022.  
1110 <https://data.census.gov/cedsci/profile?q=United%20States&g=0100000US>.
- 1111 33. Centers for Disease Control and Prevention, (CDC). 2022. “COVID-19 vaccination  
1112 demographics in the United States, National” May 16, 2022.  
1113 [https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Demographics-in-the-United-](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Demographics-in-the-United-St/km4m-vesb/about_data)  
1114 [St/km4m-vesb/about\\_data](https://data.cdc.gov/Vaccinations/COVID-19-Vaccination-Demographics-in-the-United-St/km4m-vesb/about_data).
- 1115 34. Centers for Disease Control and Prevention, (CDC). 2022. “COVID data tracker.” February  
1116 21, 2022. <https://covid.cdc.gov/covid-data-tracker>
- 1117 35. Centers for Disease Control and Prevention, (CDC). 2022. “Estimated COVID-19 burden”  
1118 February 19, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html>.
- 1119 36. T. Günther, M. Czech-Sioli, D. Indenbirken, A. Robitaille, P. Tenhaken, M. Exner, M.  
1120 Ottinger, N. Fischer, A. Grundhoff, M. M. Brinkmann, SARS-CoV-2 outbreak investigation  
1121 in a German meat processing plant. *EMBO Mol. Med.* **12**, e13296 (2020).
- 1122 37. J. Steinberg, E. D. Kennedy, C. Basler, M. P. Grant, J. R. Jacobs, D. Ortbahn, J. Osburn, S.  
1123 Saydah, S. Tomasi, J. L. Clayton, COVID-19 outbreak among employees at a meat processing  
1124 facility — South Dakota, March–April 2020. *CDC MMWR* **69**, 1015-1019 (2020).
- 1125 38. J. T. Nardini, R. E. Baker, M. J. Simpson, K. B. Flores, Learning differential equation models  
1126 from stochastic agent-based model simulations. *J. R. Soc. Interface* **18** 20200987 (2021).

- 1127 39. O. Mancur, *The Logic of Collective Action: Public Goods and the Theory of Groups* (Harvard  
1128 University Press, Cambridge, MA, 1971).
- 1129 40. L. Kalunga, E. Bulut, Z. Chen, Y. Li, R. Ivanek, Increasing vaccine uptake among employees  
1130 within the non-health related critical infrastructure sectors: A review. *Hum. Vaccin.*  
1131 *Immunother.* **19**, 2135852 (2023).
- 1132 41. Tyson Foods, “Tyson Foods to require Covid-19 vaccinations for its U.S. workforce.” (2021;  
1133 [www.tysonfoods.com/news/news-releases/2021/8/tyson-foods-require-covid-19-vaccinations-](http://www.tysonfoods.com/news/news-releases/2021/8/tyson-foods-require-covid-19-vaccinations-its-us-workforce)  
1134 [its-us-workforce](http://www.tysonfoods.com/news/news-releases/2021/8/tyson-foods-require-covid-19-vaccinations-its-us-workforce)).
- 1135 42. L. Zumbach, 2021. “McDonald’s will require U.S. office employees get the COVID-19  
1136 vaccine.” Chicago Tribune, August 11, 2021 at 5:42 pm.  
1137 [https://www.chicagotribune.com/business/ct-biz-mcdonalds-mandate-covid-19-vaccine-](https://www.chicagotribune.com/business/ct-biz-mcdonalds-mandate-covid-19-vaccine-20210811-iyy6jale2ng2dgenlz7ig3na6m-story.html)  
1138 [20210811-iyy6jale2ng2dgenlz7ig3na6m-story.html](https://www.chicagotribune.com/business/ct-biz-mcdonalds-mandate-covid-19-vaccine-20210811-iyy6jale2ng2dgenlz7ig3na6m-story.html).
- 1139 43. D. McMillon. 2021. “Walmart announces COVID-19 vaccination policy for campus office  
1140 associates.” Walmart, July 30, 2021.  
1141 [https://corporate.walmart.com/newsroom/2021/07/30/walmart-announces-covid-19-](https://corporate.walmart.com/newsroom/2021/07/30/walmart-announces-covid-19-vaccination-policy-for-campus-office-associates)  
1142 [vaccination-policy-for-campus-office-associates](https://corporate.walmart.com/newsroom/2021/07/30/walmart-announces-covid-19-vaccination-policy-for-campus-office-associates).
- 1143 44. T. Polansek. 2022. “Tyson Foods ends COVID-19 vaccine mandate for employees.” Reuters,  
1144 November 16, 2022 at 6:04 pm. [https://www.reuters.com/business/healthcare-](https://www.reuters.com/business/healthcare-pharmaceuticals/tyson-foods-ends-covid-19-vaccine-mandate-employees-2022-11-16/)  
1145 [pharmaceuticals/tyson-foods-ends-covid-19-vaccine-mandate-employees-2022-11-16/](https://www.reuters.com/business/healthcare-pharmaceuticals/tyson-foods-ends-covid-19-vaccine-mandate-employees-2022-11-16/).
- 1146 45. M. Barnes, P. E. Sax, Challenges of "Return to Work" in an ongoing pandemic. *N. Engl. J.*  
1147 *Med.* **383**, 779-786 (2020).
- 1148 46. P. L. Sacco, F. Valle, M. De Domenico, Proactive vs. reactive country responses to the  
1149 COVID-19 pandemic shock. *PLOS Glob. Public Health.* **3**, e0001345 (2023).
- 1150 47. E. K. Accorsi, J. Samples, L. A. McCauley, N. Shadbeh, Sleeping within six feet: challenging  
1151 Oregon’s labor housing COVID-19 guidelines. *J. Agromedicine.* **25**, 413-416 (2020).
- 1152 48. E. Haley, S. Caxaj, G. George, J. Hennebry, E. Martell, J. McLaughlin, Migrant farmworkers  
1153 face heightened vulnerabilities during COVID-19. *JAFSCD.* **9**, 35-39 (2020).
- 1154 49. FInd CoV Control. January 1, 2024. <https://www.foodcovidcontrol.com/FOODCTL/index.jsp>.
- 1155 50. National Center for Farmworker Health, “Agricultural Worker Demographics” (NCFH,  
1156 Health Resources and Services Administration (HRSA) of the U.S. Department of Health and  
1157 Human Services (HHS), 2018; [www.ncfh.org/agricultural-worker-demographics.html](http://www.ncfh.org/agricultural-worker-demographics.html)).
- 1158 51. S. M. Moghadas, M. C. Fitzpatrick, P. Sah, A. Pandey, A. Shoukat, B. H. Singer, A. P.  
1159 Galvani, The implications of silent transmission for the control of COVID-19 outbreaks. *Proc.*  
1160 *Natl. Acad. Sci.* **117**, 17513–17515 (2020).
- 1161 52. U.K. Health Security Agency, “COVID-19 vaccine surveillance report week 4” (UKHSA  
1162 Gateway Number GOV-11226, UK Health Security Agency, 2022;  
1163 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf)  
1164 [file/1050721/Vaccine-surveillance-report-week-4.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf)).
- 1165 53. N. Bobrovitz, H. Ware, X. Ma, Z. Li, R. Hosseini, C. Cao, A. Selemon, M. Whelan, Z. Premji,  
1166 H. Issa, B. Cheng, L. J. Abu Raddad, D. L. Buckeridge, M. D. Van Kerkhove, V. Piechotta,  
1167 M. M. Higdon, A. Wilder-Smith, I. Bergeri, D. R. Feikin, R. K. Arora, M. K. Patel, L. Subissi,  
1168 Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the  
1169 omicron variant and severe disease: A systematic review and meta-regression. *Lancet Infect.*  
1170 *Dis.* **23**, 556–567 (2023).
- 1171 54. Pfizer, “Vaccine information fact sheet for recipients and caregivers about Comirnaty  
1172 (COVID-19 vaccine, mRNA), the Pfizer-Biontech COVID-19 vaccine, and the Pfizer-  
1173 Biontech COVID-19 vaccine, bivalent (original and omicron BA.4/BA.5) to prevent  
1174 coronavirus disease 2019 (COVID-19) for individuals 12 years of age and older” (2022;  
1175 <https://labeling.pfizer.com/ShowLabeling.aspx?id=14472&format=pdf>).



- 1176 55. C. C. Kerr, R. M. Stuart, D. Mistry, R. G. Abeysuriya, K. Rosenfeld, G. R. Hart, R. C. Núñez,  
1177 J. A. Cohen, P. Selvaraj, B. Hagedorn, L. George, M. Jastrzębski, A. S. Izzo, G. Fowler, A.  
1178 Palmer, D. Delport, N. Scott, S. L. Kelly, C. S. Bennette, B. G. Wagner, S. T. Chang, A. P.  
1179 Oron, E. A. Wenger, J. Panovska-Griffiths, M. Famulare, D. J. Klein, Covasim: An agent-  
1180 based model of COVID-19 dynamics and interventions. *PLoS Comput. Biol.* **17**, e1009149  
1181 (2021).
- 1182 56. M. Arabi, Y. Al-Najjar, N. Mhaimed, M. A. Salameh, P. Paul, J. AlAnni, A. A. Abdelati, I.  
1183 Laswi, B. Khanjar, D. Al-Ali, A. Elshafeey, O. Mhaimed, Z. Burney, A. D'Souza, P. Sinha,  
1184 M. Bhatti, K. V. Pillai, M. Homssi, K. Bshesh, L. Yagan, D. Zakaria, Severity of the Omicron  
1185 SARS-CoV-2 variant compared with the previous lineages: A systematic review. *J. Cell Mol.*  
1186 *Med.* **27**, 1443–1464 (2023).
- 1187 57. M. Bielecki, G. A. G. Cramer, P. Schlagenhauf, T. W. Buehrer, J. W. Deuel, Body  
1188 temperature screening to identify SARS-CoV-2 infected young adult travellers is ineffective.  
1189 *Travel Medicine and Infectious Disease* **37**, 101832 (2020).
- 1190 58. G. A. Okoye, H. I. Kamara, M. Strobeck, T. A. Mellman, J. Kwagyan, A. Sullivan, A. S.  
1191 Byrd, B. Shokrani, H. E. Mighty, Diagnostic accuracy of a rapid diagnostic test for the early  
1192 detection of COVID-19. *Journal of Clinical Virology* **147**, 105023 (2022).
- 1193 59. S. Ahmad, Economic theory, applications and issues - estimating input-mix efficiency in a  
1194 parametric framework: application to state-level agricultural data for the United States. ISSN:  
1195 1444-8890 (2017).
- 1196 60. Center for Disease Prevention, (CDC), “Ending isolation and precautions for people with  
1197 COVID-19: interim guidance” (2022; [www.cdc.gov/coronavirus/2019-ncov/hcp/duration-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html)  
1198 [isolation.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html))
- 1199 61. Pete’s Air Purifiers. “Oransi EJ120 HEPA air purifier with carbon filter, white/black”,  
1200 January 3, 2024. [https://petesairpurifiers.com/products/oransi-ej120-hepa-air-purifier-with-](https://petesairpurifiers.com/products/oransi-ej120-hepa-air-purifier-with-carbon-filter-white-black)  
1201 [carbon-filter-white-black](https://petesairpurifiers.com/products/oransi-ej120-hepa-air-purifier-with-carbon-filter-white-black)
- 1202 62. Airpura. “P600 - germs, mold and chemicals reduction air purifier”, January 3, 2024.  
1203 <https://www.airpura.com/products/p600-germs-mold-and-chemicals-reduction>
- 1204 63. EnviroKlenz. “EnviroKlenz Air System Plus”, January 3, 2024.  
1205 [https://enviroklenz.com/product/enviroklenz-mobile-uv-](https://enviroklenz.com/product/enviroklenz-mobile-uv-model/?gc_id=1121169327&h_ad_id=572045475019&gclid=Cj0KCQiAoY-PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75AaAqwpEALw_wcB)  
1206 [model/?gc\\_id=1121169327&h\\_ad\\_id=572045475019&gclid=Cj0KCQiAoY-](https://enviroklenz.com/product/enviroklenz-mobile-uv-model/?gc_id=1121169327&h_ad_id=572045475019&gclid=Cj0KCQiAoY-PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75AaAqwpEALw_wcB)  
1207 [PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75](https://enviroklenz.com/product/enviroklenz-mobile-uv-model/?gc_id=1121169327&h_ad_id=572045475019&gclid=Cj0KCQiAoY-PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75AaAqwpEALw_wcB)  
1208 [AaAqwpEALw\\_wcB](https://enviroklenz.com/product/enviroklenz-mobile-uv-model/?gc_id=1121169327&h_ad_id=572045475019&gclid=Cj0KCQiAoY-PBhCNARIsABcz770NANY4f3xtgX2LdAkMTMBH4SrBywLkVJux8FdafgyOeDO8uqdt75AaAqwpEALw_wcB)
- 1209 64. Aerus. “Medical PRO Air Purifier”, January 3, 2024. [https://www.amazon.com/aeris-air-](https://www.amazon.com/aeris-air-Medical-Purifier-Hospital-Grade/dp/B08QW78W7C?th=1)  
1210 [Medical-Purifier-Hospital-Grade/dp/B08QW78W7C?th=1](https://www.amazon.com/aeris-air-Medical-Purifier-Hospital-Grade/dp/B08QW78W7C?th=1)
- 1211 65. BladeAir. “Blade Air HEPA Air Purifier”, January 3, 2024. [https://bladeair.com/iaq-](https://bladeair.com/iaq-solutions/hepa/)  
1212 [solutions/hepa/](https://bladeair.com/iaq-solutions/hepa/)
- 1213 66. K. VanderWaal, L. Black, J. Hodge, A. Bedada, S. Dee, Modeling transmission dynamics and  
1214 effectiveness of worker screening programs for SARS-CoV-2 in pork processing plants. *PLoS*  
1215 *One* **16**, e0249143 (2021).
- 1216 67. M. O’Driscoll, G. Ribeiro Dos Santos, L. Wang, D. A. T. Cummings, A. S. Azman, J.  
1217 Paireau, A. Fontanet, S. Cauchemez, H. Salje, Age-specific mortality and immunity patterns  
1218 of SARS-CoV-2. *Nature* **590**, 140–145 (2021).
- 1219 68. R. Verity, L. C. Okell, I. Dorigatti, P. Winskill, C. Whittaker, N. Imai, G. Cuomo-  
1220 Dannenburg, H. Thompson, P. G. T. Walker, H. Fu, A. Dighe, J. T. Griffin, M. Baguelin, S.  
1221 Bhatia, A. Boonyasiri, A. Cori, Z. Cucunubá, R. FitzJohn, K. Gaythorpe, W. Green, A.  
1222 Hamlet, W. Hinsley, D. Laydon, G. Nedjati-Gilani, S. Riley, S. van Elsland, E. Volz, H.  
1223 Wang, Y. Wang, X. Xi, C. A. Donnelly, A. C. Ghani, N. M. Ferguson, Estimates of the  
1224 severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect. Dis.* **20**, 669-677  
1225 (2020).

1226  
1227  
1228

## Acknowledgments

1229 The authors thank the Industry Advisory Council, which was assembled to guide modeling work  
1230 and comprised of executive-level leaders in the major US produce farms and food processing  
1231 companies and an official in the Centers for Disease Control and Prevention, for valuable  
1232 feedback on the structure of FInd CoV Control. The authors also thank Ms. Yu Tang (Dyson  
1233 School of Applied Economics and Management, Cornell SC Johnson College of Business,  
1234 Cornell University, Ithaca, NY, USA) for her contribution to the methodology, investigation and  
1235 writing of the original draft for the evaluation of economic impacts of interventions.

1236  
1237

### Funding:

1238 Agriculture and Food Research Initiative from the USDA National Institute of Food and  
1239 Agriculture, Competitive Grant no. 2020-68006-32875 (RI, AA, SA, MW).  
1240 Cornell Institute for Digital Agriculture (CIDA) (RI, MW)  
1241 Artificial Intelligence Institute for Next Generation Food Systems from the USDA National  
1242 Institute of Food and Agriculture, grant 2020-67021-32855 (RI, MW)  
1243 The funders had no role in the study design, data collection, and analysis, decision to publish, or  
1244 preparation of the manuscript.

1245  
1246

### Author contributions:

1247 Conceptualization: CH, RI, AA  
1248 Methodology: CH, RI, AA, CZ, DW  
1249 Investigation: CH, RI, EB, SIM  
1250 Visualization: CH, RI  
1251 Supervision: RI, AA  
1252 Writing—original draft: CH, RI  
1253 Writing—review & editing: CH, EB, SIM, CZ, AA, DW, MW, SA, RI

1254  
1255

### Competing interests:

1256 CZ is employed at iFoodDecisionSciences, Inc., which hosted the web-interface developed as an  
1257 extension of a previous version of FInd CoV Control described here (49) until December 2023;  
1258 this interface is currently hosted by iDecisionSciences, LLC. FInd CoV Control was licensed to  
1259 iDecisionSciences, Inc. under the GNU General Public License. DW is the founder of  
1260 iFoodDecisionSciences, Inc and iDecisionSciences, LLC. All other authors declare they have no  
1261 competing interests.

1262  
1263


### Data and materials availability:

1264 All data are available in the main text or the supplementary materials. R code is available under  
1265 GPL-2.0 license at <https://github.com/IvanekLab/covid-journal-code>

1266

1267  
1268


## Figures and Tables




1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277

**Figure 1. Overview of the FInd CoV Control tool.** (A) Three modules of the tool: Employee population, Work environment and Disease transmission. (B) Module building blocks: B.i Example of a shift schedule, B.ii Agent hierarchy in a food processing facility, B.iii Heatmap showing a contact network among agents in a food processing facility and relative rates of contacts, and B.iv Infection states in the COVID-19 disease transmission module. (C) List of outcomes recorded for each iteration of a simulation with the FInd CoV Control Tool.


**(A) Mean Incidence at Each Time Point**




**(D) Cumulative Incidence, Distribution**




**(B) Mean Prevalence at Each Time Point**




**(E) P. Differences, Non-Zero Baseline Runs**



**(C) Fraction of Runs > 0**




**(F) P. F. Change, Non-Zero Baseline Runs**






1279 **Figure 2. Illustration of public health outcomes for baseline (no intervention) and each of**  
1280 **the interventions in absolute terms as well as relative to the baseline.** Results for  
1281 number of symptomatic infections in a processing facility with 103 employees over the 90  
1282 days of the simulation run are shown (results for total infections are similar, apart from  
1283 scale). (A and B) The mean across all runs of the incidence (A) and prevalence (B) of  
1284 symptomatic infection, at each time point; these illustrate the dynamics over time, but also  
1285 conceal the high level of variation between runs. (C) The fraction of runs for which the  
1286 total number of symptomatic infections is greater than zero. (D) Violin plots representing  
1287 the distribution, between runs, of the *total* number of symptomatic infections; these violin  
1288 plots illustrate the bimodal nature of most distributions. (E) Violin plots representing the  
1289 distribution of *counterfactual effects* of the various interventions, i.e., the distribution of  
1290 *pairwise differences* between *corresponding* runs with and without that intervention (the  
1291 number at that intervention,  $N_I$ , minus the number at baseline,  $N_B$ ;  $N_I - N_B$ ), for runs that  
1292 *do* have one or more symptomatic infections at baseline. (F) Violin plots representing the  
1293 distribution of *pairwise fractional differences* (i.e.,  $(N_I - N_B)/N_B$ ), for runs with a non-  
1294 zero number of symptomatic infections at baseline. For three of the interventions, there is  
1295 a single positive outlier (i.e., 1 iteration out of 1,000 runs per intervention) that is cut off  
1296 by the axis limits to avoid excessively compressing the depiction of the other 11,997  
1297 points.  
1298


**(A) People Unavailable to Work Their Scheduled Shift**




**(D) P. Differences, Zero Baseline Runs**




**(B) Cumulative Worker-Shifts Missed**




**(E) P. Differences, Non-Zero Baseline Runs**




**(C) Fraction of Runs > 0**



**(F) P. F. Change, Non-Zero Baseline Runs**




1300 **Figure 3. Illustration of unavailability for baseline (no intervention) and each of the**  
1301 **interventions in absolute terms as well as relative to the baseline.** Unavailability (i.e.,  
1302 worker-shifts missed) depends not only on how many employees are infected, and how  
1303 many of those are symptomatic, but also on how likely an infected employee (whether  
1304 symptomatic or asymptomatic) is to be removed from the workforce (due to  
1305 hospitalization, or to detection and isolation). All results are for 90-day long simulation  
1306 runs. (A) The mean across all runs of the number of employees unavailable to work their  
1307 scheduled production shift, for each day of the simulation; this illustrates the dynamics  
1308 over time, but also conceals the substantial level of variation between runs. (B) Violin  
1309 plots representing the distribution, between runs, of the sum of the number of workers  
1310 unavailable to work their scheduled production shift, over all such shifts; this violin plot  
1311 illustrates the varying shapes of these distributions. (C) The fraction of runs for which the  
1312 total number of worker-shifts missed is greater than zero. (D and E) Violin plots  
1313 representing the distribution of *counterfactual effects* of the various interventions, i.e., the  
1314 distribution of *pairwise differences* between *corresponding* runs with and without that  
1315 intervention (the number at that intervention,  $N_I$ , minus the number at baseline,  $N_B$ ;  $N_I -$   
1316  $N_B$ ), for runs with zero (panel D) and non-zero (panel E) worker-shifts missed at baseline.  
1317 (F) Violin plots representing the distribution of pairwise *fractional* differences (i.e.,  $(N_I -$   
1318  $N_B)/N_B$ ), for runs with non-zero worker-shifts missed at baseline.  
1319  
1320  
1321




**Figure 4. Illustration of costs for baseline (no intervention) and each of the interventions.** All panels consist of violin plots (although in some cases, these may be sufficiently horizontally compressed that this is not obvious) representing the distribution (across runs within an intervention) of an outcome. All results are for 90-day long simulation runs. (A) Distribution of direct intervention expenses (supplies purchased and/or additional wages paid for tasks performed outside of an individual's normal scheduled working hours); these are generally relatively constant for an intervention, and are always US\$0 by definition for the baseline. (B) Distribution of production losses due to worker absences; as a result of unavailability (occurring only on days when >15% of workers miss their shift) this is almost always US\$0 in the absence of a testing intervention. Here, we can see that low to moderate levels of routine viral testing may be insufficient to interrupt transmission, but sufficient to remove significant numbers of employees through detection and isolation, and thus causing significant production losses. (C) Distribution of total costs (in US\$), which we define to be the sum of intervention expenses and production losses. (D) Fraction of production shifts (within a single run) that are "short", i.e., more than 15% of workers absent ("0%" means that in a particular run none of the shifts were "short").







**(B) Unavailable**



**(C) Intervention Expenses**




**(D) Production Loss**



**Figure 5. Regression Trees.** For all panels, the labels on the branches descending from a node represent values of the parameter listed in the node itself. Where there are only two values for a parameter, the value is sometimes only listed explicitly on the left branch, to save space; the right branch simply has the value of that parameter that the left branch does not. In all cases, branches are ordered by making the left branch the one with the *lower* average value for the outcome represented in that panel. (This does not, however, result in *all* leaves being ordered from lowest to highest, because the branches are not allowed to cross.) The value at each leaf indicates the mean value of the outcome across relevant scenarios x interventions x runs over the 90 days of the simulation run, and *n* indicates the

1349 number of runs represented by the leaf (out of 104,000 runs). (A) Total number  
1350 (Cumulative Incidence) of Symptomatic Infections, (B) Total number of Worker-Shifts  
1351 Unavailable, (C) Cumulative intervention expenses (in US\$), (D) Cumulative production  
1352 losses (in US\$).  
1353



**Figure 6. Dependence of the mean value of four major outcomes (columns), summed over the course of a 90-day simulation, on 5 selected non-user-settable parameters (rows), and on select interventions (colors).** The outcomes, columns from left to right, are total number of symptomatic infections, total number of production worker-shifts missed, effective reproduction number, and total cost in US\$. The parameters examined, rows top to bottom, are  $\psi$  (“SEVERE\_MULTIPLIER” denoting a parameter scaling the fraction of symptomatic infections that become severe);  $\mu_{IM}$ , and  $\mu_{IS}$  (mean duration of mild (“duration\_IM\_mean”) and severe (“duration\_IS\_mean”) infection, respectively);  $\beta_{IM}$

1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362

1363 (“p\_trans\_IM” denoting relative probability of transmission, per potentially infectious  
1364 contact, during mild infection); and  $\phi$  (“fraction\_ssp\_symptomatic” denoting a parameter  
1365 that pertains to how much protection from developing symptomatic disease Recovered and  
1366 Hybrid immunity provide to infected individuals). The interventions examined were  
1367 Baseline (black), Temperature Screening (dark blue), Virus Test at  $p = 0.3$  / working day  
1368 (red), Physical distancing/Biosafety at  $-40\%$   $R_0$  (dark green), and Vax + Boosting at  $p =$   
1369  $0.02/\text{day}$  (yellow). These colors are the same as those in **Figures 2, 3, and 4**, although the  
1370 line type may vary. The x-axis of each plot represents the *multiplier* applied to the  
1371 parameter in question (i.e., 0.5, 1, or 1.5 for all of the parameters depicted here).  
1372



1373  
1374  
1375  
1376  
1377

**Table 1. Summary of agent attributes.** \*‘Ramp-up’ refers to an initial increase in immunity following a vaccination event. Additional information for  $P_{\text{last, IP, } i}$  and  $P_{\text{last, IS, } i}$  is in **Table S2**. Distributions for infection stage durations are in **Table 4**. **Table S12** is a version of this table with additional notes and information on how attributes are set at simulation start and/or during the simulation.

Symbol	Description	Directly affect(s)
$A_i$	Age	Transition probabilities (see <b>Table S1</b> )
$p_{\text{stage, } i}$	Transition probabilities at full susceptibility	Asymptomatic vs. Symptomatic infection; recovery from each stage on the symptomatic path vs. further progression/ death
$D_{\text{stage, } i}$	Infection stage durations	Timing of recovery/ progression/ death
$t_{\text{event\_type, } i}$ ( $t_{V1, i}$ , $t_{V2, i}$ , $t_{B, i}$ , and $t_{R, i}$ )	Immunity event times	Protection against Any Infection ( $P_{E, i}$ ) and either overall Protection against Symptomatic Infection ( $P_{IP, i}$ ) or overall Protection against Severe Infection ( $P_{IS, i}$ )
$t_{\text{infection status, } i}$ ( $t_{E, i}$ , $t_{IA, i}$ , $t_{IP, i}$ , $t_{IM, i}$ , $t_{IS, i}$ , and $t_{IC, i}$ )	Infection and infection progression times	Timing of recovery/ progression/ death
$C_i$	Immunity trajectories	Protection against Any Infection ( $P_{E, i}$ ) and either overall Protection against Symptomatic Infection ( $P_{IP, i}$ ) or overall Protection against Severe Infection ( $P_{IS, i}$ )
$t_{\text{last, } i}$	Time of last immunity event	Immunity components (for certain immunity trajectories)
$P_{\text{last, E, } i}$	“Previous” (at the time of the last immunity event) level of Protection against Any Infection ( $P_{E, i}$ )	Current level of Protection against Any Infection, during ramp-up phases only
$P_{\text{last, IP, } i}$	“Previous” (at the time of the last immunity event) level of overall Protection against Symptomatic Infection ( $P_{IP, i}$ )	Current overall Protection against Symptomatic Infection, during ramp-up phases only
$P_{\text{last, IS, } i}$	“Previous” (at the time of the last immunity event) level of overall Protection against Severe Infection ( $P_{IS, i}$ )	Current overall Protection against Severe Infection, during ramp-up phases only
$P_{E, i}$	Protection against Any Infection	Relative susceptibility to infection (i.e., to transitioning from Not Infected to Exposed)
$P_{IP   E, i}$	Protection against Symptomatic Infection given Any Infection	Relative probability of transitioning from Exposed to Presymptomatically Infected (rather than to Asymptomatically Infected)
$P_{IS   IP, i}$	Protection against Severe Infection given Symptomatic Infection	Relative probability of transitioning from Mildly Infected to Severely Infected (rather than recovering)
$B_{\text{on time, } i}$	Boosting on time	Whether the agent has received/will receive a booster shot $T_{V2 \rightarrow B} = 5$ months after the second shot of their primary series (if any)
$V_i$	Vaccination status	Eligibility for future shots
$I_i$	Infection status	Transmissibility; hospitalization; progression, death, and recovery
$t_{\text{tested, } i}$	Most recent time tested, if any	Priority for future testing
$t_{Q, i}$	Time isolated	Eligibility for deisolation
$Q_i$	Isolation status	Eligibility for deisolation, presence or absence at work and, if applicable, shared housing (and hence, potential to transmit)

1378

1379

**Table 2. User-settable model parameters.**

Symbol	Definition (unit)	Possible values	Default value	References and Notes
$N$	Total number of agents (employee)	Farm: $\geq 4$ Facility: $\geq 7$	103	From user input (Table S11)
$N_E$	Initial number of agents who are in the Exposed state (E) (employee)	$1-N$	1	Assumed
$N_{IM}$	Initial number of agents with Mild COVID-19 symptoms (employee)	$0-(N - N_E(0))$	0	Assumed
$f_R$	Initial proportion of agents who have recovered from COVID-19 infection within the past $T_{RQ} = 1$ year (including those who were not symptomatic) (unitless)	0%–100%	69%	(32, 34, 35) (Derivation in Text S10)
$f_{V2}$	Initial proportion of agents who are fully vaccinated as part of the primary series of a COVID-19 vaccine (e.g., 2 shots of Pfizer) (unitless)	0%–100%	71%	(32, 33) (Derivation in Text S10)
$f_{V2, \text{recent}}$	Initial proportion of agents who have become fully vaccinated within the past $T_{V2 \rightarrow B} = 5$ months (unitless)	$0-f_{V2}\%$	9%	(32, 33) (Derivation in Text S10)
$f_B$	Of agents who are eligible to receive a booster shot (i.e., have completed their primary series of COVID-19 vaccination at least $T_{V2 \rightarrow B}$ ago), initial proportion who have received a booster shot (unitless)	0%–100%	45%	(32, 33) (Derivation in Text S10)
$f_{B, \text{recent}}$	Of agents who are eligible to receive a booster shot, fraction who have received a booster shot within the past $T_{V2 \rightarrow B}$ (unitless)	$0-f_B\%$	45%	(32, 33) (Derivation in Text S10)
$T$	Number of days to simulate (day)	30–150	90	
$H$	Employee housing type (categorical)	“Shared” or “Individual”	Farm: “Shared” Facility: “Individual”	
$R_{0, \text{housing}}$	Contribution of (expected) transmissions in shared housing to $R_0$ for a given level of physical distancing (High”, “Intermediate”, or “Low”) (unitless)	“High”: 1, “Intermediate” : 2, or “Low”: 4	2	When housing is “Shared”
$\lambda$	Daily force of infection from sources outside of the workforce of the operation modeled for a given level of physical distancing (“High”, “Intermediate”, or “Low”) (employee <sup>-1</sup> day <sup>-1</sup> )	“High”: 0.02, “Intermediate” : 0.002 or “Low”: 0.00002	0.002	When housing is “Individual”
$R_{0, \text{work}}$	Contribution of work transmissions to (homogeneous) $R_0$ for a given level of physical distancing (High”, “Intermediate”, or “Low”) (unitless)	“High”: 4, “Intermediate” : 6, or “Low”: 8	6	Based on physical distancing to/at work
$n_{w,c}$	Number of field workers per crew (excluding foreman) (employee)	1-100	10	Farm specific
$n_{c,s}$	Number of crews per supervisor (employee)	1-100	3	Farm specific
$n_s$	Number of supervisors (employee)	1-100	3	Farm specific
$D_{\text{weekly}}$	Total production value per week (default defined by employee number) (US \$)	0-1,000,000	247,612	Farm specific
$W$	Average hourly wage of a worker (US \$)	1-100	13.89	Farm specific
$n_{w,l}$	Number of workers per production line (employee)	2-100	10	Facility specific
$n_l$	Number of production lines (lines)	1-100	3	Facility specific
$n_{sh}$	Number of production shifts (employee)	1 or 2	2	Facility specific
$n_{cs}$	Number of cleaning shift workers (employee)	2-100	10	Facility specific
$n_{f,sh}$	Number of floating workers in a production shift	1-100	10	Facility specific

	(e.g., quality assurance technician, mechanic) (employee)			
$n_{f,all}$	Number of workers that may be present across shifts (including manager) (employee)	1-100	11	Facility specific
$D_{week}$	Total production value per week (default defined by employee number) (US \$)	1-10,000,000	784,346.67	Facility specific
$H_w$	Average hourly wage of a production line worker (US \$)	1-100	16.57	Facility specific
$F$	Indoor facility size (for estimation of the cost of a HEPA air cleaner) (sq ft)	1-100,000	1,000	Facility specific

1380

**Table 3. Numbers of agents with various immune states and histories derived from user-set parameters.** Additional details, including the equations for the calculation of  $N$  from user-set parameters, can be found in **Text S2** and **Table S2**. In the rightmost column, equations are presented for how past event times ( $t_{R,i}$ ,  $t_{V2,i}$ , and/or  $t_{B,i}$ , as applicable and relevant) and boosting status or “intention” ( $B_{\text{on time},i}$ ) are set for individuals encompassed in each of the described counts. As some of these counts are nested within other counts (e.g,  $N_{B,\text{recent}}$  within  $N_B$  within  $N_{V2,\text{older}}$ ), these attribute distributions are specified at the highest level for each they are consistent. For individuals who have received the second dose of their two-dose primary vaccination series at least  $T_{V2 \rightarrow B}$  ago,  $B_{\text{on time},i}$  indicates whether that individual *received* a booster dose “on time” when they became eligible to receive one (i.e.,  $T_{V2 \rightarrow B}$  after the second dose of their primary series). For individuals who have completed their primary series less than  $T_{V2 \rightarrow B}$  ago, or who have not completed their primary series at all, it indicates whether they *will receive* a booster dose “on time,” if and when they become eligible to receive one.

Symbol	Description	Value	Associated equation(s), for an agent $i$ who is part of this count
$N$	Total number of agents (employee)	Farm: $\geq 4$ Facility: $\geq 7$	
$N_R(0)$	Number of agents who have recovered from natural infection within the last year before the simulation start	$\text{round}(N * f_R)$	$t_{R,i} \sim \text{Uniform}(-T_{RQ}, 0)$
$N_{V2}(0)$	Number of agents who have completed a course of primary vaccination at simulation start	$\text{round}(N * f_{V2})$	
$N_{V2,\text{recent}}(0)$	Number of agents who have completed a course of primary vaccination <i>less than</i> $T_{V2 \rightarrow B} = 152$ days (5 months) prior to the start of simulation	$\text{round}(N * f_{V2,\text{recent}})$	$t_{V2,i} \sim \text{Uniform}(-T_{V2 \rightarrow B}, 0)$ $B_{\text{on time},i} \sim \text{Bernoulli}(f_B)$
$N_{V2,\text{older}}(0)$	Number of agents who have completed a course of primary vaccination <i>more than</i> $T_{V2 \rightarrow B}$ prior to the start of simulation	$N_{V2}(0) - N_{V2,\text{recent}}(0)$	
$N_B(0)$	Number of agents who have received a booster dose	$f_B * N_{V2,\text{older}}$	$B_{\text{on time},i} = 1$
$N_{B,\text{recent}}(0)$	Number of agents who have received a booster dose <i>less than</i> $T_{V2 \rightarrow B}$ prior to the start of simulation	$f_{B,\text{recent}} * N_{V2,\text{older}}$	$t_{V2,i} \sim \text{Uniform}(-2 * T_{V2 \rightarrow B}, -T_{V2 \rightarrow B})$ $t_{B,i} = t_{V2,i} + T_{V2 \rightarrow B}$
$N_{B,\text{older}}(0)$	Number of agents who have received a booster dose <i>more than</i> $T_{V2 \rightarrow B}$ prior to the start of simulation	$N_B(0) - N_{B,\text{recent}}(0)$	$t_{V2,i} \sim \text{Uniform}(-T_{1\text{st } V2 \rightarrow 0}, -(2 * T_{V2 \rightarrow B} + 1))$ $t_{B,i} = t_{V2,i} + T_{V2 \rightarrow B}$
$N_{V2,\text{older,no boost } r}$	Number of agents who have completed a course of primary vaccination <i>more than</i> $T_{V2 \rightarrow B}$ prior to the start of simulation but have <i>not</i> received a booster (despite presumably being eligible)	$N_{V2,\text{older}} - N_B(0)$	$t_{V2,i} \sim \text{Uniform}(-T_{1\text{st } V2 \rightarrow 0}, -T_{V2 \rightarrow B})$ $B_{\text{on time},i} = 0$
$N_{\text{no } V2}$	Number of agents who have not completed a primary course of vaccination	$N - N_{V2}$	$B_{\text{on time},i} \sim \text{Bernoulli}(f_B)$

1381  
1382  
1383  
1384  
1385  
1386

1387 **Table 4. Selected sensitivity parameters and derived distributions.** Gamma distributions are  
 1388 notated Gamma(shape, scale); when the mean is varied in sensitivity analysis, this is done  
 1389 by varying the scale parameter, while holding the shape parameter fixed. For more details,  
 1390 see **Text S9**. In the case of  $\beta_{IM}$ , it is the ratios between  $\beta_{IM}$  and the corresponding  
 1391 parameters for asymptomatic and presymptomatic infection ( $\beta_{IA}$  and  $\beta_{IP}$ ) that are taken  
 1392 from Moghadas et al. 2020 (51); the absolute magnitudes are rendered irrelevant by how  
 1393 we set contact rates. The derivation of coefficients for logistic decay formulas (including  
 1394 the conversion from rates per month to rates per day) is in **Text S11**. The selected value  
 1395 for parameter  $\psi$  is towards the high end of a range of estimates, as a precautionary  
 1396 measure given significant uncertainty (56).

Symbol	Definition	Formula/value	Reference
$D_{IP,i}$	Duration of Presymptomatic Infection	Gamma(1.058, 2.174)	(51)
$D_{E+IP,i}$	Incubation Period (time from infection to symptoms; model structure implies that this must be $\geq$ latent period)	max(Lognormal(1.65, 0.0192), $D_{IP,i}$ )	(51)
$D_{E,i}$	Duration of Exposed stage (Time from infection to infectiousness, i.e., latent period)	$D_{E+IP,i} - D_{IP,i}$	
$D_{IA,i}$	Duration of Asymptomatic Infection	Gamma(5, 1)	(51)
$D_{IM,i}$	Duration of Mildly symptomatic Infection	Gamma(16, 0.5)	(55)
$D_{IS,i}$	Duration of Severely symptomatic Infection	Gamma(34.0278, 0.4114)	(55)
$D_{IC,i}$	Duration of Critically symptomatic Infection	Gamma(34.0278, 0.4114)	(55)
$\mu_{IM}$	Mean duration (shape * scale) of mildly symptomatic infection.	8	(55)
$\beta_{IM}$	Relative per-contact transmissibility during Mild infection (unitless)	0.0253	(51)
$\phi$	Parameter controlling the relative magnitude of protection from symptomatic disease given infection, and protection from severe disease given symptoms, from natural and hybrid immunity (details in <b>Text S3B</b> )	0.5	Assumption
$a_{R,IS}$	Constant coefficient in logistic decay formula for overall Protection from Severe Infection granted by natural immunity	1.70512	(53)
$b_{R,IS}$	Time-dependent coefficient (1/days) in logistic decay formula for overall Protection from Severe Infection granted by natural immunity	$-0.05211/30.5 = -0.00170852459$	(53)
$a_{R,E}$	Constant coefficient in logistic decay formula for Protection from Any Infection granted by natural immunity	1.2100	(53)
$b_{R,E}$	Time-dependent coefficient (1/days) in logistic decay formula for Protection from Any Infection granted by natural immunity	$-0.1937/30.5 = -0.00635081967$	(53)
$\psi$	Relative frequency of severe infection, in the absence of any immunity, for the (original) Omicron strain relative to 2020 strains	1.2	(56)
$T_{ramp,RH}$	Interval from beginning of ramp-up of natural or hybrid immunity (if applicable) to achieving maximum protection	1 month (30.5 days)	(53)
$T_{total,R}$	Interval of complete protection following natural recovery	2 months (61 days)	(53)
$T_{V2 \rightarrow B}$	Minimum interval between completion of primary series and booster dose	5 months (152 days)	(54)
$T_{1st V2 \rightarrow 0}$	Number of days since the first individuals in the US received the secondary dose of their primary vaccine series, at the start of simulation	1 year, 61 days (426 days)	(54)
$T_{RQ}$	Period for which the user is asked to supply the fraction of workers who have recovered from natural infection in the past [duration]	1 year (365 days)	

1397



1398 **Supplementary Materials**

1399  
1400       Supplementary Materials enclosed.

1401